ACR24 Abstract Study Sponsor Statements

Abstracts are non-CME content.

0003. CLN-978, a CD19-directed T Cell Engager (TCE), Leads to Rapid and Deep B Cell Depletion and Has Broad Potential for Development in Autoimmune Diseases
Study Sponsor: Cullinan Therapeutics, Inc.
Sponsor Statement: Cullinan Therapeutics is the study sponsor and conducting and reporting on the study.

0004. Beyond Antibodies and CAR-T: Topologically Engineered, Superdimeric Antibody NK Engagers and T Cell Engagers for B Cell Depletion Demonstrating Cooperative Binding to Target and Effector Cells
Study Sponsor: Hinge Bio, Inc.
Sponsor Statement: Hinge Bio, Inc. provided the funding for the studies described in this Abstract

0006. NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases
Study Sponsor: Nurix Therapeutics
Sponsor Statement: This study was funded by a for-profit pharmaceutical biotech company, and all authors are current or past employees of the company. The company is sponsoring ongoing clinical trials, but it does not currently have any commercially-marketed products.

0007. Bromodomain 2 of BET Proteins Plays a Crucial Role in Follicular/peripheral Helper T Cell and Plasma Cell Differentiation
Study Sponsor: Mitsubishi Tanabe Pharma Corporation
Sponsor Statement: Mitsubishi Tanabe Pharma Corporation conducted the study in collaboration with Keio University School of Medicine which provided human samples obtained at Keio University Hospital.

0008. Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Study Sponsor: Kyverna Therapeutics
Sponsor Statement: Kyverna Therapeutics sponsored this study and employees of Kyverna Therapeutics conducted some of this research and are authors of this abstract.

0011. Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Study Sponsor: Kyverna Therapeutics
Sponsor Statement: Kyverna Therapeutics sponsored this study and employees of Kyverna Therapeutics conducted some of this research and are authors of this abstract.

0013. Preclinical Polypharmacology of S-1117, a Novel Engineered Fc-fused IgG Degrading Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases
Study Sponsor: Seismic Therapeutic
Sponsor Statement: All research presented in this abstract was designed, conducted and data analyzed by employees of Seismic Therapeutic.

0016. Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology
Study Sponsor: AstraZeneca
Sponsor Statement: AstraZeneca funded this study and participated in the study design, data collection, data analysis and data interpretation.

0018. Preclinical Analysisof CB-010, an Allogeneic anti-CD19CAR-T Cell Therapywith a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
Study Sponsor: Caribou Biosciences
Sponsor Statement: Caribou Biosciences is the sponsor of this research abstract.

0031. Beyond Pain and Inflammation: Intra-articular Liraglutide's Comprehensive Benefits on Synovial Health and Cartilage in Osteoarthritis Compared to Dexamethasone
Study Sponsor: 4Moving Biotech
Sponsor Statement: Work funded by 4Moving Biotech

0039. Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients' Serum
Study Sponsor: AstraZeneca
Sponsor Statement: This study was sponsored by AstraZeneca

0040. Targeting Complement Factor B (CFB) via a Novel siRNA Therapy (AZD6912) to Treat Inflammatory Arthritis
Study Sponsor: AstraZeneca
Sponsor Statement: The study was sponsored by AstraZeneca

0041. Disease Activity and Serological Inflammatory Markers Are Associated with TNF-a and IL-6-Induced Osteoclasts, but Not with RANKL-Induced Osteoclasts in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis
Study Sponsor: Gilead Sciences, Inc.
Sponsor Statement:

0048. Role of the Chemokine CCL22 in Rheumatoid Arthritis Development
Study Sponsor: GSK, Pfizer
Sponsor Statement: GSK sponsored an earlier research study in my group, part of the results have been used in the presented study. More specifically, altered CCL22 levels in the risk phase and in established RA have been observed in the collaborative study with GSK.

Pfizer

0059. Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance
Study Sponsor: UCB Pharma
Sponsor Statement: This study was funded by UCB Pharma. Editorial services provided by Costello Medical and funded by UCB Pharma.

0074. Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Study Sponsor: Pfizer
Sponsor Statement: Pfizer

0076. Early (3-Month) and Maintained (12-Month) Comparative Effectiveness of 5 Different Classes of Advanced Therapies in a Large Multinational Cohort of Real-World PsA Patients
Study Sponsor: Sponsored by Eli Lilly and Company.
Sponsor Statement: Study was sponsored by Eli Lilly and Company.

0082. Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis
Study Sponsor: Johnson and Johnson
Sponsor Statement: This study was funded by Johnson and Johnson

0084. DB-2304, an Immunomodulatory Antibody–drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models
Study Sponsor: Duality Biologics Ltd.
Sponsor Statement: This study was fully supported by Duality Biologics, LTD.

0085. A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models
Study Sponsor: Gilead Sciences
Sponsor Statement: Study was sponsored by Gilead Sciences.

0087. SYNCAR: An Engineered IL-2/IL-2R-system That Selectively Enhances CD19 CAR T Cells to Deplete B Cells and Provide Therapeutic Benefit in SLE and RA Mouse Models Without Lymphodepletion
Study Sponsor: Synthekine
Sponsor Statement: All study authors are paid employees of Synthekine.

0109. Natural History and Clinical Implications of Lupus Autoantibodies in Primary Antiphospholipid Antibody Positive Patients: Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database a
Study Sponsor: Thermofisher Scientific.
Sponsor Statement: Thermofisher Scientific provided assays free of charge in support of this project.

0134. Use of Oral Contraceptives in Females with Rheumatoid Arthritis Is Not Associated with an Increased Risk of Venous Thromboembolism: United Kingdom-population Based Study
Study Sponsor: Pfizer
Sponsor Statement: This study was sponsored by Pfizer.

0135. Rheumatoid Arthritis Associated Risk of Venous Thromboembolism Is Not Dependent on Disease Duration: United Kingdom Based Population Study
Study Sponsor: Pfizer
Sponsor Statement: This study was sponsored by Pfizer.

0136. Demographic and Clinical Characteristics of Patients with SLE Across 5 Registries – the LupusNet Federated Data Network

Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was funded by Janssen Research & Development, LLC.

0168. Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database
Study Sponsor: Chugai Pharmaceutical Co., Ltd./ Nippon Shinyaku Co., Ltd.
Sponsor Statement: Responsibility for creation of study protocol, creation of statistical analysis plan, publication of study results, and publication results.

0187. Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Study Sponsor: CVS Health
Sponsor Statement: This project was funded in-kind by CVS Health Corporation.

0195. Screening for Social Determinants of Health in Patients with SLE: A Point-of-Care Feasibility Study
Study Sponsor: GSK
Sponsor Statement: GSK was involved in the study design, collection, analysis and interpretation of data, and publication development.

0205. Cardiovascular Event Risks Among Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Study Sponsor: CVS Health
Sponsor Statement: This project was funded in-kind by CVS Health Corporation.

0220. Ultrasound-assessed Dactylitis as a Biomarker in the Early Diagnosis of Psoriatic Arthritis
Study Sponsor: This study was funded by a grant from the Instituto de Salud Carlos III, co-funded by the European Regional Development Fund (FEDER)[PI19/00176]
Sponsor Statement: The sponsor did not participate in the design, development or analysis of the study

0224. How Accurate Are Assessments by Local Radiologists of Sacroiliac Joint MRIs in Axial Spondyloarthritis and Psoriatic Arthritis in Routine Clinical Practice?- Evidence from 873 Patients in Five European Countries
Study Sponsor: Novartis Pharma AG
Sponsor Statement: The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit the abstract.

0238. Longitudinal Assessment of CD8+ T Cell Responses to SARS-CoV-2 Pre- and Post-breakthrough Infection and Its Association with COVID-19 Severity in Immunosuppressed Individuals
Study Sponsor: The study was supported by an award from the Autoimmunity Centers of Excellence, a research network supported by the National Institute of Allergy and Infectious Disease (NIAID/NIH). Grant support from the National Institutes of Health (NIH) (U19-AI110483
Sponsor Statement: NIH Sponsored.

0247. Enhanced Immunogenicity of the Recombinant Herpes Zoster Vaccine After One-Week of Mycophenolate Mofetil Discontinuation in Patients with Autoimmune Rheumatic Diseases: Interim Results from a Prospective Randomized Phase 4 Study
Study Sponsor: Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo and GSK

Sponsor Statement: Funding for this investigator initiated study was provided by GSK [NCT05879419]. GSK was provided the opportunity to review a preliminary version of this publication for factual accuracy, but the authors are solely responsible for final content and interp

0248. Recombinant Herpes Zoster Vaccine in a Large Cohort of Autoimmune Rheumatic Diseases Patients: An Interim Analysis of a Prospective Randomized Phase 4 Study
Study Sponsor: Hospital das Clinicas HCFMUSP da Faculdade de Medicina da Universidade de Sao Paulo and GSK
Sponsor Statement: Funding for this investigator initiated study was provided by GSK [NCT05879419]. GSK was provided the opportunity to review a preliminary version of this publication for factual accuracy, but the authors are solely responsible for final content and interp

0252. Prospective Study of Severe Infectious Events and Immune Reconstitution After Rituximab in Autoimmune Diseases
Study Sponsor: Grifols
Sponsor Statement: This study was funded by Grifols (the sponsor had no role in data collection or analysis and decision to submit) and FHU IMMINeNT (Lille University, CHU Lille, Inserm).

0271. Intercritical Gout Represents a Systemic Inflammatory State
Study Sponsor: Horizon
Sponsor Statement: Horizon provided funding for the biomarkers assays used in this study. They did not provide input on conduct or reporting of the study.

0278. Efficacy and Safety of Genakumab versus Compound Betamethasone in Gout: The GUARD-1 Study
Study Sponsor: GenSci Co.
Sponsor Statement:

0281. Intra-articular Treatment Combining Sustained Release Colchicine Encapsulated in Microspheres, and Ropivacaine, Is Effective in Inflammatory Arthritis in Rats
Study Sponsor: PK MED
Sponsor Statement: PK MED

0283. Prophylaxis of Gout Flares in Patients with Renal Impairment: Dosing Adjustments with Colchicine Oral Solution Informed by a Pharmacokinetic Model
Study Sponsor: Scilex Holding Company
Sponsor Statement: This work was supported by Scilex Holding Company, manufacturer of colchicine oral solution.

0290. Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: We would like to thank the patients and families who made this study possible, as well as the clinical teams who participated. The study was supported by Bristol Myers Squibb. All authors contributed to and approved this abstract; professional medical wri

0298. RAY121, a Novel Recycling Monoclonal Antibody Against Complement C1s: Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase 1a First in Human Clinical Trial in Healthy Adults
Study Sponsor: Chugai Pharmaceutical Co., Ltd.
Sponsor Statement: This study is funded by Chugai Pharmaceutical Co., Ltd. This funding source

has roles in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including wh

0303. Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

0316. Development and Evaluation of the Adult-onset Still's Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment
Study Sponsor: Chugai Pharmaceutical Co., Ltd.
Sponsor Statement: This study was sponsored by Chugai Pharmaceutical Co., Ltd. The sponsor was involved in the study design, data collection and analysis, and preparation of the abstract. The authors had full access to the data and maintained editorial control over the cont

0324. Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Study Sponsor: Cabaletta Bio
Sponsor Statement: The Study Sponsor, Cabaletta Bio, was responsible for designing the clinical protocol and funding the study. Furthermore, all correlative assessments shown herein were performed in Cabaletta Bio laboratories.

0345. Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh's Myositis Registry
Study Sponsor: Merck KGaA
Sponsor Statement: The study was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany

0346. Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls
Study Sponsor: Boehringer-Ingelheim
Sponsor Statement: This work was conducted as part of an investigator-initiated study with financial support from Boehringer-Ingelheim. However, Boehringer-Ingelheim was not involved in study design, participant selection, data analysis, or abstract writing.

0353. Identifying Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus-Based Approach
Study Sponsor: Multiple
Sponsor Statement: Lupus AIM is supported by AstraZeneca, Aurinia, Biogen, Genentech, Mallinckrodt, Novartis, and PhRMA. Sponsors were not directly involved in the conduct and reporting of the study.

0355. Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Study Sponsor: Sobi
Sponsor Statement: This analysis was funded by Sobi. Sobi reviewed and provided feedback on the abstract. The authors had full editorial control of the abstract and provided their final approval of all content.

Medical writing support was provided by Tyrone Daniel of Genesi

0356. Patient Satisfaction and Experience After a Switch to a Citrate-free High-concentration Adalimumab Biosimilar. Results from a Prospective Multicentric Real-world Study
Study Sponsor: Celltrion Healthcare France
Sponsor Statement:

0357. Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves
Study Sponsor: Sanofi
Sponsor Statement: Stefano Fiore and Amy Praestgaard are employees of Sanofi, which provided data for this analysis. None of the other authors received compensation for their work on this project. The decision to publish was that of the authors. Sanofi reviewed the content

0360. What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study
Study Sponsor: NORDIC PHARMA FRANCE
Sponsor Statement: The study was funded by NORDIC PHARMA FRANCE.

0379. Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children
Study Sponsor: Eli Lilly and Company
Sponsor Statement: The study was sponsored by Eli Lilly and Company

0381. Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment
Study Sponsor: Genetech
Sponsor Statement: Funding for this project was provided to CARRA Inc, in part by Genetech. Genetech was involved with funding and reviewing editing the abstract.

0384. Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real-World Opportunistic Study
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development

0390. Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
Study Sponsor: This study was funded by the Childhood Arthritis and Rheumatology Research Alliance
Sponsor Statement:

0391. Using Machine Learning to Predict Inactive Disease in Juvenile Idiopathic Arthritis
Study Sponsor: The study is funded by the Patient-Centered Outcomes Research Institute (25573-A).
Sponsor Statement:

0393. Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Study Sponsor: Novartis Pharmaceutical
Sponsor Statement: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The funding source was involved in study design and data analysis of this abstract. This abstract was developed in accordance with Good Publication Practice (GPP 2022) gui

0400. Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children
Study Sponsor: Bristol-Myers Squibb
Sponsor Statement: BMS provided funding for this investigator-initiated study.

0401. Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
Study Sponsor: Patient Centered Outcomes Research Institute
Sponsor Statement: This study was funded through a Patient Centered Outcomes Research Institute® (PCORI®) Award (CER-2020C1-19212). The study design, analysis, and interpretation of results presented in this abstract are solely the responsibility of the authors and do not n

0405. Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Study Sponsor: R-Pharm, JSC
Sponsor Statement: R-Pharm, JSC was involved in the study design, collection, analysis, interpretation of data, and validation of information provided in the abstract

0424. The Clinical Utility of Serum BAFF Levels in Pregnant Patients with SLE
Study Sponsor: GSK
Sponsor Statement: GSK provided funding for this study.

0447. Pregnancy Outcomes in Women Exposed to Guselkumab: Review of Cases Reported to the Manufacturer's Global Safety Database
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

0456. Use of Machine Learning to Evaluate Incremental Value of Actigraphy Data for Classifying Treatment Response in Patients with Rheumatoid Arthritis
Study Sponsor: AbbVie
Sponsor Statement: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and a

0472. Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
Study Sponsor: Alfasigma
Sponsor Statement: This research was financially supported by Alfasigma

0492. A Machine Learning Model for the Early Identification of Rheumatoid Arthritis: Development and Validation
Study Sponsor: Predicta-Med LTD
Sponsor Statement: This study was funded and conducted by Predicta-Med LTD.

0500. An Update on the Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis over a Median of 4.3 Years
Study Sponsor: Gilead Sciences, Inc., Galapagos NV
Sponsor Statement: The FINCH and DARWIN studies were co-funded by Gilead Sciences, Inc. (Foster City, CA, USA) and Galapagos NV (Mechelen, Belgium). The authors would like to acknowledge statistical programming support provided by Benjamin Pett and Mohsine El Ghazi (Galapag

0501. How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the "JAK-pot" Study)
Study Sponsor: Eli-Lilly, AbbVie, Galapagos, Pfizer
Sponsor Statement: The research presented in this abstract was financially supported by AbbVie, Galapagos, Pfizer, and Eli Lilly. These sponsors had no role in determining the research question, designing the study plan, accessing the data, or in the decision-making process

0502. Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study
Study Sponsor: Celltrion, Inc.
Sponsor Statement: The study was supported by Celltrion, Inc.

0503. Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Study Sponsor: RHADAR GbR (A Network of Rheumatologists), AbbVie Deutschland GmbH & Co. KG
Sponsor Statement: This study was funded by RHADAR GbR (A Network of Rheumatologists), Bahnhofstr. 32, 82152 Planegg, Germany. AbbVie Deutschland GmbH & Co. KG funded data analysis but was not involved in data interpretation, manuscript content, final approval, or the decis

0504. Janus Kinase Inhibitors Persist Longer Than Biologics in Rheumatoid Arthritis: Retrospective Analysis of Real-world Outpatient Data from the German Rhadar Database
Study Sponsor: RHADAR GbR (A Network of Rheumatologists), AbbVie Deutschland GmbH & Co. KG
Sponsor Statement: This study was funded by RHADAR GbR (A Network of Rheumatologists), Bahnhofstr. 32, 82152 Planegg, Germany.

0505.
UseofaMolecularSignatureResponseClassifiertoPredictInadequateResponsetoTNFiResultsinFewer Patients Prescribed TNFi
Study Sponsor: Scipher Medicine Corporation
Sponsor Statement: Scipher Medicine Corporation paid for submission of this abstract and helped develop its content.

0506. 24-week, Post-Marketing Surveillance Analysis of Upadacitinib in Japanese Patients with Rheumatoid Arthritis: The 2024 Interim Report
Study Sponsor: Abbvie
Sponsor Statement: AbbVie is the study sponsor, contributed to study design, data collection, analysis, interpretation, writing, reviewing, and approval of the final version of the abstract.

0507. Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
Study Sponsor: Eli Lilly
Sponsor Statement: Role of the Study Sponsor: The study sponsor, Eli Lilly, provided funding, data, and biosamples to support the study. They were involved in study design, interpretation of the data, as well as revising the abstract.

0508. Real-World Evidence for GP2015 in Patients with Rheumatoid Arthritis: Safety Outcomes from German Observational Data

Study Sponsor: Sandoz Hexal AG
Sponsor Statement: TBC

0511. Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0512. Co-stimulatory Blockade Causes Targeted Quantitative and Clonotypic Contractions in Extrafollicular B-cell Subsets in Seropositive RA Patients
Study Sponsor: Funded in part by BMS
Sponsor Statement: BMS funded the trial but was not involved in the conduct of the trial, the analysis of the clinical and scientific outcomes or the preparation of this abstract.

0516. Management of Elederly Patients with Rheumatoid Arthritis Treated with Tocilizumab : Comparison of Patients over and Under 75 Years Old
Study Sponsor: Chugai Pharma France
Sponsor Statement: Chugai Pharma France sponsored the study. Isabelle Idier, a Chugai Pharma France employee, participated to the writing of the protocol, SAP and abstract. IQVIA was contracted to conduct the analyses.

0518. Sustained Patient Meaningful Outcomes of Pain and Fatigue Relief and Improved Physical Functioning with Filgotinib in Rheumatoid Arthritis: A Post Hoc Analysis
Study Sponsor: Gilead Sciences Inc., Galapagos NV
Sponsor Statement: We thank the physicians and patients who participated in these studies. The FINCH 1 and FINCH 2 studies were funded by Gilead Sciences, Inc. (Foster City, CA, USA). This analysis was funded by Galapagos NV (Mechelen, Belgium). Medical writing support was

0520. Disease Duration Differentially Affects the Clinical Efficacy of Biologics and JAK Inhibitors in Rheumatoid Arthritis: The ANSWER Cohort Study
Study Sponsor: Multiple
Sponsor Statement: The study reported in this publication uses ANSWER Cohort supported by grants from 12 pharmaceutical companies (AbbVie GK, Asahi Kasei, Ayumi, Chugai, Eisai, Eli Lilly Japan K.K, Janssen K.K, Ono, Sanofi K.K, Taisho, Teijin Healthcare, and UCB Japan). Thi

0523. Distinct Peripheral Blood Immune Cell Sub-population Signatures at Baseline of Tofacitinib or Adalimumab Initiation Are Associated to Clinical Responses at 6 Months
Study Sponsor: Pfizer, ASPIRE, ID#64721055
Sponsor Statement: Pfizer had no role in study design, data collection, analysis or reporting on the results and drafting the manuscript.

0526. Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study
Study Sponsor: Dr.Reddys Laboratories
Sponsor Statement: The study conduct and abstract submission support have been funded by Dr. Reddy’s Laboratories.

0533. Using Adalimumab Serum Concentration to Choose a Subsequent DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (ADDORA-switch): Results of a Blinded Randomized

Test Treatment Trial
Study Sponsor: Funded by Netherlands Organisation for Health Research and Development and Sanquin Diagnostic Services.
Sponsor Statement:

0536. A Population Modeling and Simulation of the Effect of Obexelimab Exposure on the QTc Interval in Healthy Volunteers and Patients with Rheumatoid Arthritis or IgG4-Related Disease
Study Sponsor: Zenas BioPharma
Sponsor Statement: The studies were funded and conducted by Xencor.

Zenas BioPharma licensed the exclusive rights to obexelimab from Xencor, and is sponsoring the dissemination of these findings, including the preparation and review of this abstract for submission.

0541. Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
Study Sponsor: The CRESPA trial was carried out as an Investigator Initiated Study with support from Janssen Pharmaceutica NV, who also provided the study medication.
Sponsor Statement: The study sponsor (Janssen Pharmaceutica NV) did not participate in this ancillary analysis. It had no role in the analysis, discussion, or dissemination of these results.

0545. Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
Study Sponsor: UCB
Sponsor Statement: UCB had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

0547. EspANDE Project: Improvement of Primary Care-Rheumatology Coordination in Spondyloarthritis in a Health Area in Northern Spain
Study Sponsor: Novartis
Sponsor Statement: Financial supporting and marketing.

0548. Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
Study Sponsor: Novartis
Sponsor Statement: Part of this work was supported by an unrestricted grant by Novartis Pharma GmbH

0554. Different Prevalence of Intestinal Inflammation in Radiographic and Non-radiographic Axial Spondyloarthritis. Data from EISER Study
Study Sponsor: Johnson & Johnson Innovative Medicine
Sponsor Statement: The funder did not played part in the conduct neither in the reporting of the study

0558. Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0569. The Longitudinal Association Between Disease Activity, Function and Health-Related Quality of Life in Axial Spondyloarthritis: Results from the DESIR Cohort

Study Sponsor: The DESIR cohort is conducted as a programme hospitalier de recherche clinique (PHRC) with Assistance Publique–Hôpitaux de Paris as the sponsor. This cohort has also been supported via unrestricted grants from Pfizer France and the French society of Rheum
Sponsor Statement: The DESIR cohort is conducted as a programme hospitalier de recherche clinique (PHRC) with Assistance Publique–Hôpitaux de Paris as the sponsor. This cohort has also been supported via unrestricted grants from Pfizer France and the French society of Rheum

0574. 14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study
Study Sponsor: Augurex Life Sciences Corp
Sponsor Statement: Augurex Life Sciences Corp provided the kits for testing together with the technical time for results generation and data analysis.

0579. Association of the Presence of Active Acute Anterior Uveitis with Disease Activity in Axial Spondyloarthritis
Study Sponsor: Abbvie
Sponsor Statement: The study was supported by an unrestricted research grant from Abbvie. Judith Rademacher und Dominika Pohlmann are participants in the BIH-Charité Clinician Scientist Program funded by the Charité –Universitätsmedizin Berlin and the Berlin Institute of He

0581. Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Study Sponsor: UCB Pharma
Sponsor Statement: Study sponsored by CorEvitas, LLC and funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0582. Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Study Sponsor: UCB Pharma
Sponsor Statement: Study sponsored by CorEvitas, LLC and funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0583. Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients
Study Sponsor: Janssen Research & Development, LLC sponsored the clinical trial(s) providing data for this abstract
Sponsor Statement:

0584. Effectiveness of Tofacitinib Monotherapy versus Combination Therapy in Patients with Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondylarthritis Registry
Study Sponsor: Pfizer
Sponsor Statement: Study funded and sponsored by Pfizer and registry sponsored by CorEvitas, LLC. Medical writing support, under the direction of the authors, was provided by Caitlin Duncan, PhD, CMC Connect, a division of IPG Health Medical Communications, and was funded b

0585. Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry

Study Sponsor: CorEvitas, LLC and Eli Lilly and Company
Sponsor Statement: This study was sponsored by CorEvitas, LLC and Eli Lilly and Company.

CorEvitas has been supported through contracted subscriptions in the last two years by AbbVie, Amgen, Inc., Arena, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eli Lilly and Com

0586. Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Study Sponsor: AbbVie Inc.
Sponsor Statement: AbbVie funded this study and participated in the interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or paymen

0587. Achieving Stringent Disease Control Criteria Was Associated with Greater Work Productivity Improvements in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0588. Sex-Related Differences in Baseline Patient and Disease Characteristics: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies in Patients with Active Psoriatic Arthritis
Study Sponsor: Janssen Research & Development, LLC sponsored the clinical trial(s) providing data for this abstract.
Sponsor Statement:

0589. Time to Clinical Response to Secukinumab Across Disease Domains Among Patients with Psoriatic Arthritis: A Pooled Post Hoc Analysis of 4 Phase 3 Trials
Study Sponsor: Novartis Pharmaceuticals Corporation, East Hanover, NJ
Sponsor Statement: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The funding source was involved in study design, data analysis, drafting, and approval of this abstract. Medical writing support was provided by Coles Keeter, PhD, of Nucl

0590. Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials
Study Sponsor: Novartis Pharmaceuticals Corporation, East Hanover, NJ
Sponsor Statement: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The funding source was involved in study design, data analysis, drafting, and approval of this abstract. Medical writing support was provided by Richard Karpowicz, PhD, of

0591. Bimekizumab Maintained Efficacy Responses in Patients with Active Psoriatic Arthritis: Up to 2-Year Results from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0592. Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Study Sponsor: UCB Pharma

Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0593. Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Study Sponsor: Amgen Inc
Sponsor Statement: This study was sponsored by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Christina Mulvihill, PharmD, of Peloton Advantage, LLC, an OPEN Health company, and Claire Desborough, employee of and stockholder in Amgen Inc.

0597. Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0598. Cardio-metabolic Effects of Apremilast in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Study Sponsor: Amgen B.V.
Sponsor Statement: This study was sponsored by Amgen B.V.

0600. Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2-Year Results from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

0601. Early Improvement of Pain, Long-Term Disease Control, and Quality of Life Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib
Study Sponsor: AbbVie
Sponsor Statement: AbbVie funded these trials (NCT03104400; NCT03104374) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated i

0602. Bimekizumab Impact on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Core Domains for Patients with Psoriatic Arthritis: Results up to 2 Years of Treatment Duration
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma. The authors thank Jason Eells and Natasha de Peyrecave for their contributions.

0605. Guselkumab Binding to CD64+ IL-23–Producing Myeloid Cells Enhances Potency for Neutralizing IL-23 Signaling
Study Sponsor: The study was funded by Janssen Research & Development, LLC.
Sponsor Statement:

0607. Plasma Proteomic Analysis Reveals Type I Interferon Blockade Effects of Anifrolumab in Lupus Nephritis: Insights from a Phase 2 Trial
Study Sponsor: AstraZeneca

Sponsor Statement: This study was sponsored by AstraZeneca. Writing assistance was provided by Andrea Angstadt, PhD, of JK Associates Inc., part of Avalere Health, and funded by AstraZeneca.

0608. Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Study Sponsor: Exagen, Inc.
Sponsor Statement: This study was funded by Exagen, Inc.

0614. Bridging the Gap Between Patient's Perception on Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematous Patient
Study Sponsor: RELESSER-PROs is a national SLE registry funded by Glaxo-Smith-Kline (GSK)
Sponsor Statement: GSK provides only financial support on the creation and manteinance of registry.

0620. Clinical Efficacy and Patient-Reported Outcomes in Anti-Ro/Sjögren's Syndrome–Related Antigen a Antibody–Positive Patients with Active SLE Treated WithDeucravacitinib in the Phase 2 PAISLEY Trial
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: We would like to thank the patients and families who made this study possible, as well as the clinical teams who participated. The study was supported by Bristol Myers Squibb. All authors contributed to and approved this abstract; professional medical wri

0623. Select Patient Reported Outcome Measure Domains Enhance Immune Mediator Based Indexes That Inform Flare Risk and Disease Activity in Systemic Lupus Erythematosus
Study Sponsor: Progentec Diagnostics, Inc.
Sponsor Statement: This study was performed at Progentec Diagnostics, Inc. in conjunction with and collaboration from the Oklahoma Medical Research Foundation and the Mayo Clinic with support from NIH SBIR grant R44AI142967.

0629. Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus
Study Sponsor: F. Hoffmann-La Roche Ltd.
Sponsor Statement: This study was funded by F. Hoffmann-La Roche Ltd. Editorial assistance was provided by Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.

0633. Novel LINE-1 Reverse Transcriptase Inhibitors Can Suppress Type I Interferon Responses and Are Promising Therapeutics for Lupus
Study Sponsor: ROME Therapeutics
Sponsor Statement: ROME Therapeutics provided funding for these studies.

0635. Medical Record Natural Language Processing and Patient Biometric and Self-Reported Measures Inform an Artificial Intelligence Augmented Remote Care Management Strategy for Lupus Patients
Study Sponsor: Progentec Diagnostics, Inc. and GSK
Sponsor Statement: This study was sponsored by Progentec Diagnostics with supported study funding provided by GSK. Sponsor recruited clinical study sites, provided the recruited patients with laboratory testing, phone Apps and a linked smart watch for collecting patient bio

0636. Evaluation of Clinical, Histological and Biomarker Response After Induction Treatment of Lupus Nephritis (LN)

Study Sponsor: São Paulo State Research Support Fund - FAPESP
Sponsor Statement:

0639. Delayed Diagnosis in Systemic Lupus Erythematosus
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC.

0658. Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study
Study Sponsor: Kezar Life Sciences
Sponsor Statement: Kezar Life Sciences, Inc. funded the study and was involved in study design and development of the abstract.

0659. Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial
Study Sponsor: F. Hoffmann-La Roche Ltd
Sponsor Statement: This study was funded by F. Hoffmann-La Roche Ltd. Editorial assistance was provided by Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.

0662. Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: We would like to thank the patients and families who made this study possible, as well as the clinical teams who participated. The study was supported by Bristol Myers Squibb. All authors contributed to and approved this abstract; professional medical wri

0663. Treatment Patterns and the Prevalence of Kidney Biopsy-Confirmed LN in Patients with SLE and Proteinuria: A Multicenter Cohort Study
Study Sponsor: Funding: GSK 217855
Sponsor Statement: Role of the Study Sponsor: GSK funded the analytical component of the study, and was involved in study design, results interpretation, and publication development.

0671. Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study
Study Sponsor: Biogen
Sponsor Statement: This study was funded by Biogen (Cambridge, MA, USA). Writing and editorial support were provided by Selene Medical Communications (Macclesfield, UK), funded by Biogen.

0672. Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE
Study Sponsor: Cincinnati Children's Hospital Medical Center
Sponsor Statement:

0673. BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients
Study Sponsor: Study was an IIT, iCell Gene Therapeutics, Inc. provided CAR
Sponsor Statement: iCell Gene Therapeutics, Inc.

0676. Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research
Study Sponsor: F. Hoffmann-La Roche Ltd
Sponsor Statement: Lupus Ethnography Research has been funded by F. Hoffmann-La Roche Ltd. Editorial assistance was provided by Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.

0678. Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: The SENSCIS and INBUILD trials were supported by Boehringer Ingelheim.

0696. MRI DAVIX Index Is an Imaging Biomarker for Endothelial Damage of Systemic Sclerosis Digital Ulcers
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: Funder, contribution to study design, no presentation bias.

0701. Diagnostic Performances of Vascular Biomarkers Soluble Fms-like Tyrosine Kinase (sFlt-1) and Placental Growth Factor (PlGF) in Scleroderma Renal Crisis: A Case Control Study
Study Sponsor: Département Medico-Universitaire (DMU) Biophygen (Dominique Prié, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris), MERRI SERI 202
Sponsor Statement: The project was supported by a grant from the Département Medico-Universitaire (DMU) Biophygen (Dominique Prié, Hôpital Cochin, Assistance Publique des Hôpitaux de Paris), MERRI SERI 202. The sponsor had no role in the design and conduct of the study, the

0702. AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud's & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Stud
Study Sponsor: Aisa Pharma, Inc.
Sponsor Statement: The role of the Study Sponsor was to design the clinical trial and fund the research. The research was independently conducted at Flinders Medical Center in Adelaide, Australia. The study sponsor and all study personnel and patients were blinded throug

0703. Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud's, Primarily Due to Systemic Sclerosis
Study Sponsor: Aisa Pharma, Inc.
Sponsor Statement: The sponsor of this study, Aisa Pharma, was involved in the design and development of this study. However the study was conducted independently at Flinders Medical Center in Adelaide, Australia, and was randomized, prospective, double-blind, and study p

0747. Clofutriben to Improve the Benefit-Risk Profile of Prednisolone in Patients with Polymyalgia Rheumatica
Study Sponsor: Sparrow Pharmaceuticals
Sponsor Statement: Sparrow Pharmaceuticals employees led the design, conduct, analysis, and reporting of the clinical trial.

0748. Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica
Study Sponsor: Sanofi and Regeneron Pharmaceuticals
Sponsor Statement: Sponsored by Foundation for Advancing Science, Technology, Education and Research, funded by Sanofi and Regeneron Pharmaceuticals Inc.

0750. Corticosteroid Withdrawal Using Tocilizumab and Its Association with Autoantibody Profile in Takayasu Arteritis: A Multicenter, Single-arm, Prospective Study
Study Sponsor: Chugai Pharmaceutical Co
Sponsor Statement: This study was funded by Chugai Pharmaceutical Co.

0755. Characteristics Associated with Long-Term Glucocorticoids Use in Patients with New Onset Polymyalgia Rheumatica
Study Sponsor: Sanofi and Regeneron Pharmaceuticals
Sponsor Statement: Sponsored by Foundation for Advancing Science, Technology, Education and Research; funded by Sanofi and Regeneron Pharmaceuticals Inc.

0767. Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis
Study Sponsor: University Hospital Foundation Medical Research Competition
Sponsor Statement: This work was funded by the University Hospital Foundation Medical Research Competition (UHFMCR), at the University of Alberta, Canada. UHFMCR did not play any role in the conduct or reporting of this study.

0770. Efficacy and Safety of Upadacitinib in Patients with Giant Cell Arteritis (SELECT-GCA): A Double-Blind, Randomized Controlled Phase 3 Trial
Study Sponsor: AbbVie
Sponsor Statement: AbbVie and the authors thank the patients, study sites, and investigators who participated in this clinical trial (NCT03725202). AbbVie funded this trial and participated in the study design, research, analysis, data collection, interpretation of data, re

0773. Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration
Study Sponsor: Citryll BV
Sponsor Statement: Citryll BV

0775. A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
Study Sponsor: Amgen Inc,
Sponsor Statement: Study and abstract were funded by Amgen Inc.

0778. Comprehensive Immune Profiling of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Patients with Autoimmune Disease
Study Sponsor: Kyverna Therapeutics
Sponsor Statement: Kyverna Therapeutics sponsored this study and employees of Kyverna Therapeutics conducted some of this research and are authors of this abstract.

0783. Spatial Reconstruction of Interstitial Lung Disease
Study Sponsor: 10x Genomics
Sponsor Statement: This work was partially supported by 10x Genomics.

0790. CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study
Study Sponsor: Hikma Pharmaceuticals
Sponsor Statement: The Study Sponsor provided colchicine (drug) and placebo for our double-blind trial, but had no input on study design, data collection, patient interaction, or data interpretation.

0792. Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA
Study Sponsor: Biosplice Therapeutics, Inc.
Sponsor Statement: Biosplice Therapeutics, Inc., designed, funded and monitored the study. Biosplice also conducted data management and statistical analysis.

0796. Development and Evaluation of Machine Learning Prediction Models for Hospitalizations Due to Opioid-Related Harms Among New Users with Rheumatic and Musculoskeletal Diseases
Study Sponsor: Funded by a FOREUM Career Research Grant and NIHR. MJ is supported by an NIHR Advanced Fellowship [NIHR301413]. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the UK Department of Health and
Sponsor Statement: Funded by a FOREUM Career Research Grant and NIHR. MJ is supported by an NIHR Advanced Fellowship [NIHR301413]. The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS or the UK Department of Health and

0801. Neutrophil Activation as a Novel Marker of Lung Disease in Rheumatoid Arthritis
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: Role of the Study Sponsor: The author(s) meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). This was an independent, investigator initiated study supported by Boehringer Ingelheim Pharmaceuticals

0805. Results from the Certolizumab-pegol Pregnancy Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project
Study Sponsor: UCB provided funding to support the research study
Sponsor Statement: UCB provided funding to support the research study

0809. The Utility of the sFlt1:PlGF Ratio to Rule out and Predict Preeclampsia in Women with Lupus
Study Sponsor: GSK
Sponsor Statement: GSK provided funding for this study but had no access to data nor input on the analysis.

0816. Distinct Transcript and Protein Dysregulation Patterns in Dermatomyositis and Systemic Lupus Erythematosus
Study Sponsor: AstraZeneca
Sponsor Statement: AstraZeneca partially funded this study under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Environmental Health Sciences and National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National I

0818. Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
Study Sponsor: Novartis
Sponsor Statement: Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

0820. The Classification in Axial Spondyloarthritis Inception Cohort Study: Performance of the 2009 Assessments in Spondyloarthritis International Society Classification Criteria
Study Sponsor: Abbvie, Amgen, Eli-Lilly, Janssen, Novartis, Pfizer, UCB
Sponsor Statement: None of the study sponsors (Abbvie, Amgen, Eli-Lilly, Janssen, Novartis, Pfizer, UCB) had any role in the design, conduct, analysis, or reporting of the CLASSIC study.

0823. A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis
Study Sponsor: Bristol-Myers Squibb
Sponsor Statement: Bristol-Myers Squibb provided funding support and study-drug for the conduct of the clinical trial.

0827. Oral Corticosteroid-Sparing Effects of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Results up to 7.4 Years from the Long-Term Access Programme
Study Sponsor: GSK
Sponsor Statement: GSK was involved in study design and implementation, as well as data collection, analysis, interpretation, writing the study report and reviewing this abstract. GSK did not place any restrictions on access to data or statements made in the abstract. All a

0828. Efficacy of Eosinophil-Targeting Therapies on Specific Disease Manifestations of Eosinophilic Granulomatosis with Polyangiitis in the Phase 3 MANDARA Trial
Study Sponsor: AstraZeneca
Sponsor Statement: This analysis was funded by AstraZeneca, which was involved in the study design and interpretation of the study results and funded medical writing support. AstraZeneca also reviewed the publication, without influencing the opinions of the authors, to ensu

0836. NF-κB Inducing Kinase Is a Therapeutic Target for Autoimmune Diseases by Orchestrating Both B Cell and T Follicular Helper Cell Responses
Study Sponsor: AstraZeneca
Sponsor Statement: The study was sponsored by AstraZeneca.

0844. Effectiveness and Safety of the Recombinant Zoster Vaccine in Patients ≥18 Years of Age with Systemic Lupus Erythematosus or Multiple Sclerosis
Study Sponsor: GlaxoSmithKline Biologicals SA
Sponsor Statement: This project was initiated and funded by GlaxoSmithKline Biologicals SA. The investigators developed the protocol, independently conducted the data analysis and interpretation, and wrote the abstract. The sponsor reviewed and provided input on the protoco

0851. Diagnostic Ultrasound Enthesitis Tool (DUET) for Psoriatic Arthritis: The Distribution of Elementary Lesions Is Influenced by Site
Study Sponsor: The study was supported by unrestricted research grant to GRAPPA sponsored by Abbvie, Eli Lilly, Novartis, Pfizer and Janssen
Sponsor Statement: The study was supported by unrestricted research grant to GRAPPA sponsored by Abbvie, Eli Lilly, Novartis, Pfizer and Janssen. The sponsors did not play any role in the design, conduct or analysis of the results.

0858. Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)
Study Sponsor: Lilly
Sponsor Statement: Lilly France financially supported this study. The funding source had no role in the design or conduct of the study; the collection, management, analysis, or interpretation of the data; or the preparation, revision, or approval of the manuscript.

0870. The Impact of Body Mass Index on Cardiovascular Risk in Rheumatoid Arthritis Varies Across Anticitrullinated Protein Antibody Status and Biologic Use
Study Sponsor: Pfizer
Sponsor Statement: The sponsor only provided funding for the study. There was no involvement in data collection, analysis, or abstract drafting

0871. Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients - "The PreCePRA Study"
Study Sponsor: The study was supported by UCB Biopharma SPRL, Brussels, Belgium, according to the items outlined in the IIS

Contract.
Sponsor Statement: UCB Biopharma SPRL had no role in the study design, data collection, analysis, or manuscript preparation but approved the final manuscript for publication.

0875. Targeted IL-15 Muteins Provide Selective Expansion of KIR+ CD8 Regulatory T Cells, with the Potential to Ameliorate Disease in Autoimmune Patients with Deficient CD8 Treg Populations
Study Sponsor: Mozart Therapeutics
Sponsor Statement: The abstract describes development of a potential therapeutic at Mozart Therapeutics. The work was entirely funded by, and all authors are employees of, Mozart Therapeutics.

0876. C-CAR168 as a Novel Anti-CD20/BCMA Bispecific Autologous CAR-T Therapy for the Treatment of Autoimmune Diseases
Study Sponsor: AbelZeta Inc.
Sponsor Statement: This abstract was funded by AbelZeta Inc.

0877. Zasocitinib (TAK-279) Displays High Levels of TYK2 Inhibition and No Inhibition of JAK 1/3 Compared with Licensed TYK2 and JAK Inhibitors
Study Sponsor: Takeda Development Center Americas, Inc.
Sponsor Statement: This study was funded by Takeda Development Center Americas, Inc.

0879. A Novel, Oral, Allosteric Inhibitor of Tyrosine Kinase 2 (TYK2) Demonstrates In Vitro Potency, Selectivity, and In Vivo Efficacy in Mouse Models of Psoriasis
Study Sponsor: Atomwise Inc.
Sponsor Statement: The research in the abstract was performed and funded by Atomwise Inc.

0881. Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica
Study Sponsor: N.A
Sponsor Statement:

0882. Brepocitinib, a Selective TYK2/JAK1 Inhibitor Under Evaluation for the Treatment of Dermatomyositis, Reduces Inflammatory Cytokine Signaling and Interferon-induced Apoptosis in Primary Human Epidermal Keratinocytes
Study Sponsor: Priovant Therapeutics Inc.
Sponsor Statement: Priovant Therapeutics Inc. funded the work being presented in this abstract.

0887. Identification of Rare Variants in Lupus-causing Genes in a Mixed Paediatric and Adult Connective Tissue Disease Cohort
Study Sponsor: Jannsen Research and Development
Sponsor Statement: Jannsen Research and Development funded the whole-exome sequencing experiments, but did not have any role in the design of the experiments, the interpretation of the results or writing of the abstract.

0902. Novel Role of TYK2mechanism in SLE Pathogenesis via T Cell and B Cell Pathways
Study Sponsor: Alumis Inc
Sponsor Statement: Commercial support was provided by Alumis Inc.

0932. IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model
Study Sponsor: Gilead Sciences, Nurix Therapeutics
Sponsor Statement: Study was jointly sponsored by Gilead Sciences and Nurix Therapeutics

0933. NLRP3 Inflammasome Promotes Release of Peptidyl Arginine Deiminases2 and 4 from Human Neutrophils
Study Sponsor: AstraZeneca
Sponsor Statement: This study was sponsored by AstraZeneca.

0934. Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies
Study Sponsor: Olatec Therapeutics, Inc.
Sponsor Statement: Dapansutrile is currently in clinical development for the indication in gout and other diseases by Olatec Therapeutics.

0935. Molecular Degraders of Extracellular Protein (MoDEsTM) Rapidly and Effectively Remove Interstitial IgG and Disease-Relevant Immune Complexes Through Endo-lysosomal Degradation in the Liver
Study Sponsor: Biohaven Pharmaceuticals
Sponsor Statement: Biohaven Pharmaceuticals conducted the research and analyzed the data.

0939. A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis
Study Sponsor: Silo Pharma, Inc. (Englewood Cliffs, NJ, USA: CEO: Eric Weisblum).
Sponsor Statement: Silo Pharma supported this work through a sponsored research agreement.

0941. DC-9476, a Novel Selective BRD4(BD2) Inhibitor, Improves Arthritis Scores in Preclinical Models of Rheumatoid Arthritis by Regulating Key Inflammatory Pathways
Study Sponsor: DeepCure Inc.
Sponsor Statement: This study was supported by DeepCure Inc. DeepCure was the responsible party in the study design, data collection, and the analysis and reporting of study results.

0944. Targeting Defective Macrophages to Restore Resolution of Inflammation in Rheumatoid Arthritis -Perspectives for an Autologous Secretome Therapy
Study Sponsor: Med Inn Pharma
Sponsor Statement: Med Inn Pharma

0945. Involvement of Cellular Senescence in Rheumatoid Arthritis-associated Interstitial Lung Disease of SKG Mice
Study Sponsor: Bayer
Sponsor Statement: Only funding.

0947. REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis
Study Sponsor: Recludix Pharma
Sponsor Statement: The research described in this abstract was funded by Recludix Pharma

0953. Establishment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension Specific Endothelial Cells Through iPSCs and Their Functional and Molecular Analyses

Study Sponsor: GlaxoSmithKline K.K., Actelion Pharmaceuticals Japan Ltd, Janssen Pharmaceutical K.K.
Sponsor Statement: This research has the following financial relationships to disclose.

Grant/Research funding from: GlaxoSmithKline K.K., Actelion Pharmaceuticals Japan Ltd, Janssen Pharmaceutical K.K.

0955. Inhibition of Interleukin-2-Inducible T Cell Kinase with Soquelitinib Demonstrates Efficacy in Preventing Lung Damage in Murine Models of Systemic Sclerosis
Study Sponsor: Corvus pharmaceuticals
Sponsor Statement: The study was sponsored by Corvus pharmaceuticals. The sponsor provided financial support and resources for the research. They were involved in the design and conduct of the study, including data collection, analysis, and interpretation of the results. Ad

0968. Proteomic, Transcriptomic, and Functional Characterization of Circulating Extracellular Vesicles in Progressive Scleroderma Interstitial Lung Disease
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: Boehringer Ingelheim funded this study through a competitive grant call and had input in the design of the study

0975. Prevalence and Management of Patients with Comorbidities and Frailty in New Onset Polymyalgia Rheumatica
Study Sponsor: Sponsored by Foundation for Advancing Science, Technology, Education and Research, funded by Sanofi and Regeneron Pharmaceuticals Inc.
Sponsor Statement:

0977. Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older
Study Sponsor: GSK
Sponsor Statement: The study funder, GSK, had the right to comment on the study design, interpretation of data, and manuscript content.

1000. Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Study Sponsor: Sandoz
Sponsor Statement: This study was partly sponsored by Sandoz. Sandoz had no influence on the data collection, statistical analyses or preparation of this abstract and had no access to raw data.

1009. Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept
Study Sponsor: Kevin L. Winthrop Pfizer, AbbVie, Union Chimique Belge (UCB), Eli Lilly & Company,

Galapagos, GlaxoSmithKline (GSK), Roche, Gilead, BMS, Regeneron, Sanofi, AstraZeneca, Novartis, Moderna,

BMS, Pfizer, Jeremy A. Hawkins: None declared, Adriana Weinberg G
Sponsor Statement: This study was supported through an Investigator-Initiated Research Grant from Bristol

Myers Squibb. The project described was supported by the National Center for Advancing Translational

Sciences (NCATS), National Institutes of Health, United States, t

1011. Use of the Shingrix Vaccine Among Patients with Inflammatory Arthritis and Risk of Cardiovascular Events Following Herpes Zoster
Study Sponsor: AbbVie
Sponsor Statement: AbbVie funding this study and participated in the study design, research, analysis, interpretation of data, drafting, reviewing, and approval of this abstract. All authors had access to relevant data and participated in the drafting, review, and approval

1020. Health Inequalities Exist Between the United States and Europe for Patients with Axial Spondyloarthritis
Study Sponsor: Pfizer
Sponsor Statement: Data collection was undertaken by Adelphi Real World as part of the Adelphi axSpA V Disease Specific Programme™ (DSP), to which Pfizer Inc. was one of multiple subscribers. The axSpA V DSP dataset is an Adelphi-owned product; Pfizer Inc. did not influence

1043. A Prospective Study on Early Diagnosis of Inflammatory Rheumatic Diseases Using an Enhanced Online Questionnaire System (RhePort 1.3)
Study Sponsor: RheumaDatenRheport GbR (Rhadar.de - A Network of Rheumatologists). Grant by Novartis Pharma.
Sponsor Statement: This study was funded by the RheumaDatenRheport GbR (Rhadar.de - A Network of Rheumatologists), Bahnhofstr.

32, 82152 Planegg, Germany. RheumaDatenRheport GbR has received a grant for this study from Novartis Pharma

1045. Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Study Sponsor: CVS Health
Sponsor Statement: This project was funded in-kind by CVS Health Corporation.

1047. Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Study Sponsor: CVS Health
Sponsor Statement: This project was funded in-kind by CVS Health Corporation.

1051. Healthcare Costs and Resource Utilization Associated with Long-term Medium-to-high Dose Oral Corticosteroid Use in Patients with Dermatomyositis or Polymyositis
Study Sponsor: Janssen Global Services
Sponsor Statement: This study was funded by Janssen Global Services, LLC

1052. Challenges and Opportunities in Post-Pandemic Remote Therapeutic Monitoring for Musculoskeletal Disease
Study Sponsor: Amgen Inc.
Sponsor Statement: This study was done with sponsorship support from Amgen Inc.

1085. Pharmacokinetics and Pharmacodynamics of Tigulixostat in Participants with Mild, Moderate, and Severe Renal Impairment

Study Sponsor: LG Chem
Sponsor Statement: This study was funded by LG Chem.

1090. Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy
Study Sponsor: Horizon Therapeutics plc (now Amgen, Inc.)
Sponsor Statement: The study sponsor was involved in study design, data analysis, and data interpretation of the MIRROR RCT study; design, analysis, data interpretation, and abstract writing for the post hoc analysis reported here.

1093. Risk of Dementia in Patients with Gout: Potential Impact of Survival Bias
Study Sponsor: Horizon Pharma
Sponsor Statement: Horizon Pharma funded the project. The company was not involved in the design, analysis, or interpretation of results.

1100. Coronary Dual-Energy Computed Tomography for the Detection of Monosodium Urate Crystal Deposition in the Arteries of Individuals with and Without Gout (CORODECT): A Multi-Center Prospective Imaging Study
Study Sponsor: Horizon
Sponsor Statement: This study was supported in part by an investigator-initiated research grant from Horizon. The funder did not have any role in the design, conduct, or analysis of the study, or the decision to submit this abstract.

1121. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AMG 329, a Monoclonal Antibody, in Conventional and Plasmacytoid Dendritic Cell-Mediated
Study Sponsor: This study was sponsored by Horizon Therapeutics plc (Now Amgen Inc.).
Sponsor Statement:

1131. Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis
Study Sponsor: Nimbus Discovery, Inc. and Takeda Development Center Americas, Inc.
Sponsor Statement: This study was funded by Nimbus Discovery, Inc.* and Takeda Development Center Americas, Inc.

*Nimbus refers to the group of entities including Nimbus Therapeutics LLC, Nimbus Discovery, Inc. and Nimbus Lakshmi, Inc. (NB: Nimbus Lakshmi, Inc. was acquire

1132. Guselkumab and Golimumab Combination Induction Therapy in Ulcerative Colitis Results in Early Local Tissue Healing That Is Sustained Through Guselkumab Maintenance Therapy
Study Sponsor: This study was sponsored by Janssen Research & Development, LLC
Sponsor Statement:

1134. First-in-Human Evaluation of the Safety, Tolerability and Pharmacokinetics of the T Cell Receptor Signal Modulator AX-158
Study Sponsor: Artax Biopharma, Inc.
Sponsor Statement: This study was commissioned and sponsored by Artax Biopharma Inc.

1135. Deucravacitinib in Plaque Psoriasis: 4-Year Efficacy Results by Prior Biologic Treatment in the Phase 3 POETYK PSO-1, PSO-2, and Long-Term ExtensionTrials
Study Sponsor: Bristol Myers Squibb

Sponsor Statement: We would like to thank the patients and families who made this study possible, as well as the clinical teams who participated. The study was supported by Bristol Myers Squibb. All authors contributed to and approved this abstract; professional medical wri

1136. Efficacy And Safety of Guselkumab Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results of the Galaxi 2 & 3 Phase 3 Studies
Study Sponsor: This study was sponsored by Janssen Research & Development, LLC
Sponsor Statement:

1137. Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: We would like to thank the patients and families who made this study possible, as well as the clinical teams who participated. The study was supported by Bristol Myers Squibb. All authors contributed to and approved this abstract; professional medical wri

1166. Characteristics, Treatments, and Outcomes of Patients with Dermatomyositis from Two Large, Nationwide US Cohorts
Study Sponsor: Pfizer
Sponsor Statement: This study received funding from Pfizer.

1169. Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study
Study Sponsor: Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna Austria
Sponsor Statement: The study Sponsor funded the study and overlooked the conduction of the study.

1184. Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the Knee
Study Sponsor: Pacira BioSciences, Inc
Sponsor Statement: Pacira BioSciences, Inc., who acquired Flexion Therapeutics and the gene therapy PCRX-201 (originally named FX201) in 2021, funded this abstract.

1194. Treatment Effect of Lorecivivint Across Multiple Trials in Patients with Knee OA: A Meta-analysis
Study Sponsor: Biosplice Therapeutics, Inc.
Sponsor Statement: Biosplice Therapeutics, Inc., designed, funded and monitored the studies. Biosplice also conducted data management and statistical analysis.

1197. Safety and Immunogenicity of an Active Anti-IL-6 Immunotherapy in a Phase 1 Clinical Trial in Knee Osteoarthritis Patients
Study Sponsor: This abstract was funded by biotech company "Peptinov"
Sponsor Statement: This study was funded by biotech company "Peptinov"

1199. Diclofenac Sodium 1% Gel Improves Physical Function in the Performance of Important Activities of Daily Living in Patients with Hand or Knee Osteoarthritis
Study Sponsor: Haleon
Sponsor Statement: This abstract has been submitted by Haleon and describes a post-hoc analysis of 3 clinical trials originally sponsored by Novartis.

1205. OARSI Initiative to Develop Classification Criteria for Early-Stage Symptomatic Knee OA (EsSKOA): What Should Be Considered in the Differential Diagnosis of EsSKOA?
Study Sponsor: Grünenthal; Viatris Inc
Sponsor Statement: We would like to acknowledge the funding support for the EsSKOA initiative by Grünenthal and Viatris Inc. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, revie

1211. An Evaluation of the Efficacy, Pharmacokinetics and Safety, of the Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist RTX-GRT7039 – a Placebo-controlled Study in Patients with Osteoarthritis Knee Pain
Study Sponsor: This clinical trial was conducted by Mestex, which was subsequently acquired by Grunenthal GmbH.
Sponsor Statement: This clinical trial was funded by the sponsor, Mestex AG (a Swiss biotechnology company), which was subsequently acquired by Grunenthal GmbH.

1216. Subcutaneous Methylnaltrexone Treatment of Opioid-Induced Constipation in Adults with Rheumatic Conditions
Study Sponsor: Salix Pharmaceuticals
Sponsor Statement: Study sponsored by Salix Pharmaceuticals. Medical writing support provided by MB Moncrief, Synchrony Medical Communications, LLC; funded by Salix Pharmaceuticals.

1218. Randomized, Double-Blind, Placebo-Controlled Confirmatory Phase 3 Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) in Fibromyalgia
Study Sponsor: Tonix Pharmaceuticals
Sponsor Statement: This Phase 3 trial was funded by Tonix Pharmaceuticals, the sponsor for the conduct and reporting of the study

1234. Patient and Physician Preferences for Pain Relief Treatment for Moderate-to-Severe Pain Associated with Knee Osteoarthritis: A Qualitative Exploration
Study Sponsor: Grünenthal GmbH
Sponsor Statement: This study was funded by a research grant from Grünenthal GmbH. The employees of the study sponsor contributed to the study conception and design and provided editorial input in relation to abstract preparation.

1238. Role of Patient Reported Outcomes in Predicting Disease Relapse at One Year in Those with Polymyalgia Rheumatica
Study Sponsor: N.A
Sponsor Statement:

1239. Innovative Patient Empowerment: Evaluating the Effect of a Physician-created Educational Video and To-do Lists on Promoting Preventive Health Measures in Rheumatic Disease Patients
Study Sponsor: Abbvie, Galapagos
Sponsor Statement: This study was sponsored with a conditional grant by Abbvie and Galapagos.

1242. Qualitative Patient Interview Study in Patients with Systemic Lupus Erythematosus to Assess Patient Perception of Fatigue and Skin-Related Symptoms
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: This study and abstract were funded by Bristol Myers Squibb. Bristol Myers Squibb employees were involved in the study design, the collection, analysis, and interpretation of data, the review of the abstract, and the decision to submit.

1243. A Patient-Focused Program for Using Steroids Wisely
Study Sponsor: To be completed later
Sponsor Statement:

1247. Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren's Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations
Study Sponsor: This study was funded by Otsuka Pharmaceutical Development and Commercialization, Inc.
Sponsor Statement: The sponsor was involved in the study design, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

1250. Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren's Disease
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: This study and abstract were funded by Bristol Myers Squibb. Bristol Myers Squibb employees were involved in the study design, the collection, analysis, and interpretation of data, the review of the abstract, and the decision to submit.

1251. Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives
Study Sponsor: Galapagos NV and Alfasigma S.p.A.
Sponsor Statement: We thank the physicians and patients who participated in this survey. The study is funded by Galapagos NV (Mechelen, Belgium) and Alfasigma S.p.A. (Mechelen, Belgium). Medical writing support was provided by Debbie Sherwood, BSc, CMPP (Aspire Scientific,

1253. Patterns of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus with or Without Concurrent Fibromyalgia
Study Sponsor: US Centers for Disease Control and Prevention
Sponsor Statement: 19U48DP006396 - SIP21-008: STRIVE: Systemic Lupus Targets Related to Improving Vital Endpoints.

1U01DP006700 - HEALTH: Harnessing Epidemiology to Advance Lupus Treatment and Health

1254. The Impact of Eosinophilic Granulomatosis with Polyangiitis on the Health-Related Quality of Life of Patients and Their Ability to Work: Evidence from a Real-World Survey in Clinical Practice
Study Sponsor: AstraZeneca
Sponsor Statement: This Disease Specific Program (DSP) is a wholly-owned Adelphi Real World product, of which AstraZeneca is one of multiple subscribers. Medical writing support, under the direction of the authors, was provided by Katherine Wood, PhD, of Ashfield MedComms,

1279. Cerebrovascular Accidents in Pediatric and Adult Systemic Lupus Erythematosus: A Comparison of Epidemiology and Outcomes
Study Sponsor: This abstract was funded by the Lupus Research Alliance (LRA) Diversity in Lupus Research Career Development Award
Sponsor Statement:

1294. Using Case-Based Continuing Education to Identify and Address Knowledge and Behavior Gaps in ANCA-associated Vasculitis
Study Sponsor: This activity was supported by educational funding provided by Amgen.
Sponsor Statement:

1331. Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?
Study Sponsor: Janssen Pharmaceuticals
Sponsor Statement: This study was sponsored by Janssen Pharmaceuticals.

1333. Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study
Study Sponsor: The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Pfizer Canada- Founding sponsor since 2007; AbbVie Corporation since 2011; Sandoz Biopharmaceuticals Canada since 2019; O
Sponsor Statement: The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Pfizer Canada- Founding sponsor since 2007; AbbVie Corporation since 2011; Sandoz Biopharmaceuticals Canada since 2019; O

1336. Risk of Malignancy Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Study Sponsor: Pfizer
Sponsor Statement: This work was supported by Pfizer general research grant.

1338. Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study
Study Sponsor: GlaxoSmithKline Biologicals SA
Sponsor Statement: This work was supported by an Investigator Sponsored Study grant from GlaxoSmithKline Biologicals SA.

1360. Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Study Sponsor: Janssen Global Services
Sponsor Statement: This study was supported by Janssen Global Services, LLC.

1361. The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis
Study Sponsor: Pfizer
Sponsor Statement: The sponsor only provided funding for the study. The sponsor was not involved in the study design, data collection, analysis and interpretation or manuscript drafting

1362. Comparative Effectiveness of Upadacitinib versus Other JAK Inhibitors in Patients with Rheumatoid Arthritis in a Global Real-World Setting
Study Sponsor: AbbVie, Inc.
Sponsor Statement: Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Rheumatoid Arthritis Disease Specific Programme (DSP). The DSP is a wholly owned Adelphi product and is the intellectual property of Adelphi Real W

1363. Prevalence and Predictors of Orthopaedic Surgery in Rheumatoid Arthritis After 12-Years' Follow-Up (ESPOIR Cohort)
Study Sponsor: An unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology. Pfizer. Abbvie. Lilly. and more rec
Sponsor Statement: No specific funding was received for this study

1366. Methotrexate Maintenance in Rheumatoid Arthritis, Two Years After Initiation of a First Targeted Therapy: Results from the Prospective STRATEGE2 Study
Study Sponsor: NORDIC PHARMA FRANCE
Sponsor Statement: The study was funded by NORDIC PHARMA FRANCE.

1367. Maintained Improvement of Disease Activity and Patient-reported Outcomes (PROs) with Filgotinib in Patients with Rheumatoid Arthritis (RA) in the Real World: Up to 2-year Interim Data from FILOSOPHY
Study Sponsor: Alfasigma S.p.A.
Sponsor Statement: We thank the physicians and patients who participate in this study.

The study is funded by Alfasigma S.p.A. Medical writing support was provided by Debbie Sherwood, BSc, CMPP (Aspire Scientific, Bollington, UK), and funded by Alfasigma S.p.A. Publication

1369. Persistence, Effectiveness and Treatment Patterns of Upadacitinib in over 2600 Australian Rheumatoid Arthritis Patients: A Retrospective Analysis from the OPAL Dataset
Study Sponsor: AbbVie
Sponsor Statement: AbbVie funded this study and contributed to its design, interpretation of data, and the review and approval of this publication.

1370. Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset
Study Sponsor: AbbVie Pty Ltd
Sponsor Statement: AbbVie funded this study and contributed to its design, interpretation of data, and the review and approval of this publication.

1376. Comparison of the Efficacy of DMARDs in Phase 3 Trials of Different Populations Used in FDA Approvals for Rheumatoid Arthritis Since 2010
Study Sponsor: Aclaris Therapeutics Inc.
Sponsor Statement: Study sponsor provided time and electronic resources to conduct this research.

1380. Rapid, Clinically Meaningful Pain Improvements Are Associated with Improvements in Other Patient-Reported Outcomes in RA Patients Treated with Upadacitinib
Study Sponsor: AbbVie Inc.
Sponsor Statement: AbbVie funded these trials (NCT02629159, NCT02726847, and NCT03086343) and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data a

1381. Elimination of CD45RChigh T and B Cells by anti-CD45RC mAb Lead to Efficient Control of Experimental Rheumatoid Arthritis
Study Sponsor: AbolerIS Pharma
Sponsor Statement:

1382. Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Study Sponsor: AnaptysBio, Inc
Sponsor Statement: The role of the study sponsor, AnaptysBio, included funding and analysis.

1384. Disease-modifying Antirheumatic Drugs and Risk of Incident Interstitial Lung Disease Among Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
Study Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers

R01 AR080659, R01 AR077607, P30 AR070253, and P30 AR072577), the National, Heart, Lung, and Blood Institute (grant number R01 HL122255), the R. Bruce and Joan M. Mickey R
Sponsor Statement:

1385. A Novel Oral 3D-Printed Delayed- and Extended-Release Tofacitinib (T19) for the Treatment of Rheumatoid Arthritis and Related Inflammatory Diseases
Study Sponsor: The clinical study and abstract is supported from Triastek Inc.
Sponsor Statement:

1386. Olokizumab in Real Clinical Practice: Efficacy and Safety
Study Sponsor: R-Pharm, JSC
Sponsor Statement:

1387. Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study
Study Sponsor: R-Pharm, JSC
Sponsor Statement: Was funded by R-Pharm, JSC.

1388. CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis
Study Sponsor: Bristol-Myers Squibb sponsored this study but did not partake in the study design, data collection, experiment conduction, or data analysis.
Sponsor Statement:

1389. Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter
Study Sponsor: Celltrion Healthcare
Sponsor Statement: This abstract was funded by Celltrion Healthcare. This is an unrestricted grant. Celltrion did not have any influence on the design of the study or the contents of the abstract.

1392. Safety and Efficacy of Upadacitinib (UPA) in Japanese Patients with Rheumatoid Arthritis (RA) and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-SUNRISE Study
Study Sponsor: AbbVie
Sponsor Statement: AbbVie, Inc was the trial sponsor, contributed to trial design, data collection, analysis & interpretation, and to writing, reviewing, and approval of final version. No honoraria or payments were made for authorship.

1393. Relationship Between Disease Activity and Adverse Events in Rheumatoid Arthritis: An Integrated Post Hoc Analysis of Upadacitinib Phase 3 Trials
Study Sponsor: AbbVie Inc.
Sponsor Statement: AbbVie and the authors thank the patients, study sites, and investigators who participated in these clinical trials (NCT02629159, NCT03086343, NCT02706951, NCT02706847, NCT02706873, NCT02675426). AbbVie funded these studies and participated in the study d

1399. A First-in-Human Clinical Trial Evaluating the Safety and Pharmacokinetics of SOL-116, a Novel Humanized Monoclonal Antibody Targeting Bile Salt-Stimulated Lipase for the Treatment of RA
Study Sponsor: Lipum AB
Sponsor Statement: This study was sponsored by Lipum AB, Sweden, who provided funding, study medication, and overall project management. The sponsor also participated in the design and conduct of the trial, data collection and analysis, and interpretation of the study resul

1404. Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
Study Sponsor: PPD, part of Thermo Fisher Scientific
Sponsor Statement: The authors are employees of Thermo Fisher Scientific

1410. Using Social Listening to Understand the Patient Voice: The Daily Impacts of Sjögren's Disease
Study Sponsor: Amgen Inc.
Sponsor Statement: Amgen Inc.

1411. Impact of Patient and Physician Alignment on Sjögren's Disease Severity, a Real-World Survey on Patients' Clinical Outcomes and Health-Related Quality of Life
Study Sponsor: Novartis Pharma AG
Sponsor Statement: This study was sponsored by Novartis Pharma AG, Basel, Switzerland.

Data collection was undertaken by Adelphi Real World as part of the Adelphi Sjögren's Disease Specific Programme™ (DSP), to which Novartis was one of multiple subscribers. The Sjögren's D

1413. Pilot Trial of Ustekinumab for Primary Sjogren's Syndrome
Study Sponsor: Janssen
Sponsor Statement: Janssen financially funded the study

1421. Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sjögren Disease
Study Sponsor: Funding: GSK, UKRI MRC-EMINENT-GSK grant (ref. 6591924)
Sponsor Statement: Role of the Study sponsor: GSK was involved in study design, collection, analysis, and interpretation of data, and publication development.

1426. Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren's Syndrome: Comparison to SLE and Rheumatoid Arhtritis
Study Sponsor: IMIDomics Inc.
Sponsor Statement:

1427. Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren's Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

1428. A Post-hoc Analysis of Two Phase 2 Randomized Controlled Trials in Patients with Active Sjogren's Disease Exploring the Novel Composite Endpoint Sjögren's Tool for Assessing Response (STAR)
Study Sponsor: Novartis Pharma; European Horizon 2020 Innovative Medicines Initiative
Sponsor Statement: The interventional phase 2 clinical studies LOUiSSe and TwinSS were sponsored by Novartis Pharma and gave rise to the datasets analyzed and reported herein.

1448. The Proportion of Inflammatory Back Pain Patients with an Abnormal Sacral MRI in a Community-Based Primary Care Setting
Study Sponsor: UCB
Sponsor Statement: UCB, a pharmaceutical biotech corporation, has provided financial support for all aspect of this study.

1454. Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US
Study Sponsor: Novartis Pharmaceuticals Corporation
Sponsor Statement: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The funding source was involved in study design, data analysis, drafting, and approval of this abstract. Medical writing support was provided by Statlog Econometrics, and

1456. Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort
Study Sponsor: This study received funding from National Institute for Health Research CS-2016-16-016, UCB and Janssen.
Sponsor Statement: The funder has not had direct input into the design of the study or collection, analysis and interpretation of data. They have no role in the writing of the manuscript.

1457. Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care - 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial
Study Sponsor: Novartis
Sponsor Statement: STAMP is an investigator-initiated study sponsored by an unrestrictive grant from Novartis.

1458. Synovial Transcriptomic Sex-Specific Differences in the Response to Biologics in Psoriatic Arthritis Patients
Study Sponsor: This study is an academic study (investigator-initiated trial).

The sponsor is the university hospital (Cliniques universitaires Satint-Luc).

Janssen company support by giving a grant, without implication in the design and management of the trial.
Sponsor Statement:

1462. Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

1463. Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies
Study Sponsor: Amgen Inc.
Sponsor Statement: This study was sponsored by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Rebecca Lane, PhD, of Peloton Advantage, LLC, an OPEN Health company, and Rebecca Miles, PhD, employee of and stockholder in Amgen Inc.

1464. Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Study Sponsor: Janssen
Sponsor Statement: Janssen funded this study.

1465. The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial

Study Sponsor: Amgen Inc.
Sponsor Statement: This study was funded by Amgen Inc.

1466. Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks - Data from a Phase 4 Trial
Study Sponsor: Amgen Inc.
Sponsor Statement: This study was sponsored by Amgen Inc.

1467. Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials
Study Sponsor: AbbVie
Sponsor Statement: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approving the abstract. All authors had access to relevant data and participated in the drafting, review, and approv

1469. Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain
Study Sponsor: Janssen
Sponsor Statement: This study was sponsored by Janssen

1470. Patients with Psoriatic Arthritis from a Phase 4 Head-to-Head Study Stratified by Nail Involvement
Study Sponsor: Eli Lilly and Company
Sponsor Statement: Eli Lilly and Company had a role in study design, data analysis, data collection, data interpretation, and writing of the report.

1472. Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

1473. Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

1474. Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Study Sponsor: The study was funded by Janssen Research & Development, LLC.
Sponsor Statement:

1475. Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial
Study Sponsor: Eli Lilly and Company
Sponsor Statement:

1477. Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
Study Sponsor: Nimbus Discovery, Inc. and Takeda Development Center Americas, Inc.
Sponsor Statement: This study was funded by Nimbus Discovery, Inc.* and Takeda Development Center Americas, Inc. Writing assistance was provided by Alexandra Smith, MSc at Oxford PharmaGenesis, Oxford, UK and funded by Takeda Development Center Americas, Inc.

*Nimbus refers

1478. Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

1479. Effectiveness of B/tsDMARDs Including Ixekizumab Per Line of Therapy and Concomitant CsDMARDs in Psoriatic Arthritis: Real-World Data from a Prospective Observational Study
Study Sponsor: Eli Lilly and company
Sponsor Statement: This study was sponsored by Eli Lilly and Company.

1480. Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

1481. Safety of Secukinumab in Patients with Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa: Updated Pooled Data from 69 Clinical Trials
Study Sponsor: Novartis Pharma AG, Basel, Switzerland
Sponsor Statement: This study was sponsored by Novartis Pharma AG, Basel, Switzerland.

1482. Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Study Sponsor: Novartis Pharmaceuticals Corporation, East Hanover, NJ
Sponsor Statement: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The funding source was involved in study design, data analysis, drafting, and approval of this abstract. Medical writing support was provided by Coles Keeter, PhD, of Nucl

1490. Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Study Sponsor: Exagen, Inc.
Sponsor Statement: This study was funded by Exagen, Inc.

1492. Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE
Study Sponsor: AstraZeneca
Sponsor Statement: This study was sponsored by AstraZeneca. Writing assistance was provided by Katey Glunt, PhD, of JK Associates Inc., part of Avalere Health, and funded by AstraZeneca.

1495. Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study
Study Sponsor: AstraZeneca
Sponsor Statement: This study was sponsored by AstraZeneca.

1496. Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus
Study Sponsor: The study was funded by Janssen Research & Development, LLC.
Sponsor Statement:

1509. Validation of a Score for the Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus: Data from a Latin American Lupus Cohort
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC.

1510. Impact of Active Lupus Nephritis on the Quality of Life of Patients from a Latin American Lupus Cohort
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC.

1511. Lupus Nephritis and Response to Treatment in Latin America
Study Sponsor: Janssen Research & Development, LLC
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

1530. Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant
Study Sponsor: This study (GSK Study 217537) was funded by GSK.
Sponsor Statement:

1537. Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
Study Sponsor: Ventus Therapeutics
Sponsor Statement: Ventus Therapeutics funded the scope of work presented.

1542. Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus
Study Sponsor: Amgen, Inc.
Sponsor Statement: This trial was sponsored by Amgen, Inc. Writing and editorial assistance were provided by Claire Strothman, PhD of AlphaBioCom, a Red Nucleus company, and were funded by Amgen, Inc.

1543. Improvements in BILAG Musculoskeletal and Mucocutaneous Domains at Week 48 in a Phase 2 Double-Blind Placebo-Controlled Trial of ABBV-599 (Elsubrutinib + Upadacitinib Combination) and Upadacitinib Monotherapy for Treatment of Moderately to Severely Active
Study Sponsor: AbbVie
Sponsor Statement: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and appr

1545. Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2
Study Sponsor: Aurinia Pharmaceuticals Inc.
Sponsor Statement: This work was funded by Aurinia Pharmaceuticals Inc.

1546. Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Study Sponsor: Genentech, Inc
Sponsor Statement: This study was funded by Genentech, Inc. Editorial assistance was provided by Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.

1551. Efficacy of Belimumab on Different Phenotypes of Joint and Skin Manifestations of Systemic Lupus Erythematosus: Preliminary Data from a Multicenter, Nationwide, Cohort of Patients: The BElimumab in Real Life Setting Study-New Joint and Skin (BeRLISS-NeJS)
Study Sponsor: GSK
Sponsor Statement: This research was supported by GSK

1552. Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: We would like to thank the patients and families who made this study possible, as well as the clinical teams who participated. The study was supported by Bristol Myers Squibb. All authors contributed to and approved this abstract; professional medical wri

1553. Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Study Sponsor: the healthcare business of Merck KGaA, Darmstadt, Germany
Sponsor Statement: The study was sponsored by the healthcare business of Merck KGaA, Darmstadt, Germany

1554. Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials
Study Sponsor: This study (GSK Study 217537) was funded by GSK.
Sponsor Statement:

1555. Sustained Functional Assessment of Chronic Illness Therapy–Fatigue Response in Patients with SLE Receiving Anifrolumab Alongside Standard Therapy
Study Sponsor: AstraZeneca
Sponsor Statement: This study was sponsored by AstraZeneca. Writing assistance was provided by Vasileios Stamou, PhD, and Katey Glunt, PhD, of JK Associates Inc., part of Avalere Health, and funded by AstraZeneca.

1570. Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung
Study Sponsor: AbbVie Inc
Sponsor Statement: This research was sponsored by AbbVie Inc. S.K. and Y.B. analyzed the data and participated in the drafting/editing of the draft.

1571. Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Study Sponsor: AbbVie Inc
Sponsor Statement: This research was sponsored by AbbVie Inc. S.K. and Y.B. who took part in analysing the data and participated in the drafting/editing of the draft.

1586. The Relationship Between the Presence, Quantity and Distribution of Cutaneous Telangiectasia and Other Vascular Manifestations of Systemic Sclerosis
Study Sponsor: This work was supported by a grant from the US Department of Defence and the Scleroderma Clinical Trials Consortium.
Sponsor Statement:

1588. Validation of a Lung Ultrasound Interpretation Criteria for Interstitial Lung Disease Screening in Systemic Sclerosis and Inflammatory Myopathy
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: This research was supported through an investigator initiated study award from Boehringer Ingelheim

1596. Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis
Study Sponsor: AstraZeneca
Sponsor Statement: This analysis was funded by AstraZeneca, which was involved in the study design and interpretation of the study results and funded medical writing support. AstraZeneca also reviewed the publication, without influencing the opinions of the authors, to ensu

1601. Changing Spectrum of Systemic Therapies for Eosinophilic Granulomatosis with Polyangiitis from 2006-2023
Study Sponsor: This analysis was supported in part by AstraZeneca and GSK.
Sponsor Statement: This analysis was supported in part by AstraZeneca and GSK through funding provided to the Vasculitis Clinical Research Consortium. This included input on study design.

1603. Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial
Study Sponsor: Amgen
Sponsor Statement: The ADVOCATE study was funded by ChemoCentryx, Inc. (a wholly owned subsidiary of Amgen Inc.). Amgen supported this post hoc analysis.

1604. Utilizing Machine Learning with Claims Data to Diagnose and Quantify the Prevalence of Eosinophilic Granulomatosis with Polyangiitis
Study Sponsor: AstraZeneca
Sponsor Statement: This analysis was funded by AstraZeneca, which was involved in the study design and interpretation of the study results and funded medical writing support. AstraZeneca also reviewed the publication, without influencing the opinions of the authors, to ensu

1605. Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis
Study Sponsor: AstraZeneca
Sponsor Statement: This analysis was funded by AstraZeneca, which was involved in the study design and interpretation of the study results and funded medical writing support. AstraZeneca also reviewed the publication, without influencing the opinions of the authors, to ensu

1606. Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data

Study Sponsor: AstraZeneca
Sponsor Statement: This analysis was funded by AstraZeneca, which was involved in the study design and interpretation of the study results and funded medical writing support. AstraZeneca also reviewed the publication, without influencing the opinions of the authors, to ensu

1623. Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Study Sponsor: ROCHE
Sponsor Statement:

1640. ACR/EULAR 2022 Classification Criteria Compared to the ACR 1990 Classification Criteria in the ARTESER Registry of Giant Cell Arteritis
Study Sponsor: ROCHE FARMA S.A. provided financial support for this study. Spanish Foundation of Rheumatology provided assistencial support for the study
Sponsor Statement: ROCHE FARMA S.A. provided unrestricted grant

1642. A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Study Sponsor: Accelerating Medicines Partnership (AMP)
Sponsor Statement: This abstract was developed in a research collaboration between Johns Hopkins University and Exagen, Inc. The data for the analysis is publicly available from the AMP partnership.

1647. Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission
Study Sponsor: An unrestricted research grant from UCB-pharma
Sponsor Statement: An unrestricted grant from UCB. UCB did not have any influence on study design, data collection, data interpretation or writing of this abstract or further reports.

1650. IL-33 Expands Plasma Cells, Disrupts Germinal Centers and Increases Autoantibody Production
Study Sponsor: Regeneron Pharmaceuticals
Sponsor Statement: This study was sponsored by Regeneron Pharmaceuticals. All authors are current or former employees of Regeneron and may hold stock or stock options in the company. AJM, MAS and JMO are officers of Regeneron Pharmaceuticals.

1659. Shared Lung and Joint T Cell Repertoire in Early Rheumatoid Arthritis Driven by Cigarette Smoking
Study Sponsor: Janssen Research and Development
Sponsor Statement: The study has been performed as a joint effort by Ghent University -VIB and Janssen Research and Development- J&J. The work has been supported, in part, by Janssen Research and Development - J&J.

YA & VT are employees and shareholders of Janssen Researc

1672. The Evaluation of SLE Outcome Measures in Telemedicine
Study Sponsor: This work was funded by U.S. Department of Defense, award #: W81XWH-21-1-0468.
Sponsor Statement:

1677. Safety and Efficacy of FNS007, a Non-T Cell Receptor Contacting Peptide, for Patients with Active Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial

Study Sponsor: Hebei Fitness Biotechnology Limited Company
Sponsor Statement: The study was funded by Hebei Fitness Biotechnology Limited Company

1678. Efficacy, Safety, Pharmacokinetics of Anti-CD40 Antibody Abiprubart in Patients with Rheumatoid Arthritis: A Phase 2, Randomized, Placebo-Controlled 12-week-treatment Proof-of-Concept Study
Study Sponsor: Kiniksa Pharmaceuticals
Sponsor Statement:

1679. Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: This study was supported by Bristol Myers Squibb

1681. Safe Switching from Originator Tocilizumab to MSB11456 Tocilizumab Biosimilar in Subjects with Moderate-to-Severe Rheumatoid Arthritis: Efficacy, Safety and Immunogenicity Data Following Treatment Transition in a Pivotal, Randomized, Double-blind, Phase I
Study Sponsor: Fresenius Kabi SwissBioSim GmbH
Sponsor Statement: Fresenius Kabi SwissBioSim GmbH was involved in the conception and design of work, the acquisition, analysis, and interpretation of data, and drafting of the abstract.

1682. Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor
Study Sponsor: Eli Lilly and Company and Rigel Pharmaceuticals
Sponsor Statement: This study was funded by Eli Lilly and Company and Rigel Pharmaceuticals

1685. The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis
Study Sponsor: BMS
Sponsor Statement: BMS provided samples only.

1693. Change in Forced Vital Capacity at Week 12 or 24 Has Prognostic Value for Outcome at Week 52 in Patients with Autoimmune Disease-Related Interstitial Lung Diseases
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: The SENSCIS and INBUILD trials were supported by Boehringer Ingelheim.

1695. Efficacy of Upadacitinib in Patients with Giant Cell Arteritis: Subgroup Analysis of the SELECT-GCA Phase 3 Trial
Study Sponsor: AbbVie Inc.
Sponsor Statement: AbbVie and the authors thank the patients, study sites, and investigators who participated in this clinical trial (NCT03725202). AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, re

1698. Assessment of the Remission Maintenance After Tocilizumab Withdrawal in Polymyalgia Rheumatica Patients Receiving a 6-month Treatment
Study Sponsor: The funders of this study were the French National Program for Clinical Research and the study sponsor (ie, the Brest University Hospital). Roche-Chugai Pharmaceutical provided an unconditional grant for the study and donated the tocilizumab used for the
Sponsor Statement: Roche-Chugai

1701. STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity
Study Sponsor: AstraZeneca
Sponsor Statement: This study is sponsored by AstraZeneca

1718. Randomization to Holding versus Continuing (JAKi, IL17) and Autoimmune Patient Responses to COVID-19 Boosters: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study
Study Sponsor: Lilly, Novartis, BMS, Pfizer, AbbVie
Sponsor Statement: This study was jointly funded by Eli Lilly, Novartis, Bristol Myers Squibb, Pfizer and AbbVie.

1720. Herpes Zoster Risk Following Initiation of Immunosuppressive Therapy Among Adults with Rheumatic Disease
Study Sponsor: GlaxoSmithKline Biologicals SA
Sponsor Statement: GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO-000613) and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took in charge all costs associated with the developme

1721. Recombinant Zoster Vaccine Uptake in US Adults with Rheumatic Disease: A Mixed Methods Analysis
Study Sponsor: GlaxoSmithKline Biologicals SA
Sponsor Statement: GlaxoSmithKline Biologicals SA funded this study (study identifier: VEO-000679) and was involved in all stages of study conduct, including analysis of the data. GlaxoSmithKline Biologicals SA also took in charge all costs associated with the development a

1722. Machine Learning-based Risk Stratification Tool to Predict Early Flare for Rheumatic and Musculoskeletal Diseases
Study Sponsor: This study is sponsored by UK Research and Innovation (UKRI) Engineering and Physical Sciences Research Council (EPSRC), grant number: EP/Y019393/1
Sponsor Statement:

1733. Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Study Sponsor: Cabaletta Bio
Sponsor Statement: Cabaletta Bio was involved in the study design, collection, analysis and interpretation of data, and development of abstracts/publications.

1743. What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Study Sponsor: Yes
Sponsor Statement: This study was supported by Janssen Global Services, LLC.

1745. Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis
Study Sponsor: Study was sponsored by Pfizer Inc.
Sponsor Statement: Study was sponsored by Pfizer Inc. Pfizer employees, along with the academic authors, designed the study, analyzed and interpreted the data, and were involved in the writing of the abstract and the decision to submit the abstract.

1753. A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Ref
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: Bristol Myers Squibb is sponsoring the clinical trial and funding this abstract

1756. What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF Inhibitor or an
Study Sponsor: UCB
Sponsor Statement: The EuroSpA collaboration has been supported by Novartis Pharma AG since 2017 and UCB Biopharma SRL since 2022. This EuroSpA study was financially supported by UCB. No financial sponsors had any influence on the data collection, statistical analyses, abst

1757. Bimekizumab Treatment Resulted in Improvements in MRI Inflammatory and Structural Lesions in the Sacroiliac Joints of Patients with Axial Spondyloarthritis: 52-Week Results and Post Hoc Analyses from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

1758. Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

1759. Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study
Study Sponsor: Novartis Pharma AG
Sponsor Statement: The study was sponsored by Novartis Pharma AG, Basel, Switzerland.

1760. A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Mitogen-activated Protein Kinase-Activated Protein Kinase 2 (MK2) Inhibitor in Active Ankylosing Spondylitis
Study Sponsor: The study was designed, conducted, and study data analyzed by the study sponsor, Bristol Myers Squibb. The abstract was written by the principal investigator, who is presenter of the abstract, with the support of the study sponsor.
Sponsor Statement: The study was designed, conducted, and study data analyzed by the study sponsor, Bristol Myers Squibb. The abstract was written by the principal investigator, who is presenter of the abstract, with the support of the study sponsor.

1784. T-bet Expressing B Cells as a Putative Prognostic and Therapeutic Biomarker for Human SLE
Study Sponsor: Hellenic Foundation for Research and Innovation (HFRI), 3rd Call for HFRI PhD Fellowships (Fellowship Number: 5148) and Hellenic Society of Rheumatology & Professional Association of Rheumatologists (Protocol Number: 1064).
Sponsor Statement:

1793. SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages
Study Sponsor: AstraZeneca

Sponsor Statement: This study was conducted at AstraZeneca facility, performed by the company's full-time employee and have the cost associated to it all funded by AstraZeneca.

1795. Immune Complexes-Mediated Activation of Neutrophils in Systemic Lupus Erythematosus Is Dependent on RNA Recognition by TLR8
Study Sponsor: Gilead
Sponsor Statement: Role of Study Sponsor: The sponsor, Gilead, provided funding for the study, and participated in the design and interpretation of the data, as well as provided input on the abstract.

1798. CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis
Study Sponsor: This work was supported by the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus Network. AMP includes the following government, foundation and industry partners: AbbVie Inc., Arthritis Foundation, Bristol-Myers Squibb Company, Fo
Sponsor Statement: The study sponsors had no role in collection, analysis, or interpretation of the data.

1799. In VitroEvidence for the Restoration of Glucocorticoid Sensitivity by Toll-Like Receptor 7 and 8 Inhibition in Systemic Lupus Erythematosus
Study Sponsor: EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany.
Sponsor Statement: EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100004755) was collaboratively involved in and funded the study.

1801. Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Study Sponsor: UCB Pharma and Biogen Inc.
Sponsor Statement: This study was funded by UCB Pharma and Biogen Inc. Medical writing and editorial support was provided by Costello Medical and funded by UCB Pharma and Biogen Inc.

1808. Not Only Type-I Interferon Regulated Genes Are Differentially Expressed in Circulating Monocytes from Active Lupus Nephritis Patients
Study Sponsor: Project funded by Minciencias, Colombia, contract 919-2019. Scholarship Sapiencia
Sponsor Statement:

1810. Modulation of Type I Interferon Signaling by Anifrolumab Alters the Spatial Immune Landscape in Cutaneous Lupus Erythematosus
Study Sponsor: 10x Genomics
Sponsor Statement: This study is partially funded by 10X Genomics

1814. Understanding Monocyte Derived Macrophages in the Skin of SSc Patients Through Single Cell Analysis of Blister Fluid Immune Cell Populations
Study Sponsor: Aurinia Pharmaceuticals
Sponsor Statement: dd

1815. Leveraging Novel Systemic Sclerosis Disease Signatures to Build a Humanized Drug Discovery Funnel
Study Sponsor: All authors are employees of AbbVie.
Sponsor Statement: All authors are employees of AbbVie. The design, study conduct, and financial

support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

1837. Baseline Multiome Sequencing of CD45RO+CD45RA-CD4+ T Cell Reveals Distinct Immune Profiles Associated with Subsequent Response to Secukinumab Treatment
Study Sponsor: Novartis
Sponsor Statement: Investigator-initiated study funded by Novartis.

1838. M5542: A Potent CD80, CD86, and OX40L Antagonist Fusion Molecule for the Treatment of Autoimmune Diseases
Study Sponsor: EMD Serono Research and Development Institute, Inc.
Sponsor Statement: EMD Serono Research and Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA (CrossRef Funder ID:10.13039/100004755)

1841. Preclinical Evaluation of ALLO-329: Allogeneic CD19 CAR T Cells Expressing an Anti-Rejection CD70 CAR for the Treatment of Autoimmune Diseases
Study Sponsor: Allogene Therapeutics
Sponsor Statement: This study was sponsored by Allogene Therapeutics.

1848. Characterization of Treg Phenotype, Function and Its Transcriptome Signatures in Treatment-naïve Rheumatoid Arthritis
Study Sponsor: The work was supported by Department of Science & Technology - Science and Engineering Research Board(DST-SERB), India [SERB/F/0253/2016-17 to Vir Singh Negi] and intramurally by Jawaharlal Institute of Postgraduate Medical Education & Research JIPMER [JI
Sponsor Statement:

1854. TCR-Nck Modulators: Pioneering Oral Modulation of T Cell Receptor Activation Holding the Promise of Treating Autoimmune Diseases
Study Sponsor: Artax Biopharma, Inc
Sponsor Statement: This work was funded by Artax Biopharma, Inc.

1859. Clonal Relationships Between Tph and Tfh Cells in Patients with SLE and in Murine Lupus
Study Sponsor: Merck & Co., Inc
Sponsor Statement: This study was funded by Merck & Co., Inc. The sponsor was involved in the design, analysis, and data interpretation of the human studies.

1861. CD8T Cells Depletion Promotes Human Tph/Tfh Cells Proliferation and Sjogren Syndrome Like Symptoms Without Graft versus Host Diseases in PBMC Transferred-humanized Mice
Study Sponsor: Mitsubishi Tanabe Pharma Corporation
Sponsor Statement: Mitsubishi Tanabe Pharma Corporation

1864. S-4321, a Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Study Sponsor: Seismic Therapeutic
Sponsor Statement: All research presented in this abstract was designed, conducted and data analyzed by employees of Seismic Therapeutic.

1870. Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Study Sponsor: Alira Health
Sponsor Statement:

1884. VIVA QI: Vaccination In Vasculitis: Applying a Quality Improvement Approach
Study Sponsor: Pifizer
Sponsor Statement: Pfizer provided funding which supported data collection for this study, funds were not used for any other purpose.

1889. Prevalence of Physician-Diagnosed versus Clinically Confirmed Primary Sjögren's Syndrome (SS) Among Adults in the United States
Study Sponsor: Otsuka Pharmaceutical Development and Commercialization, Inc.
Sponsor Statement: The sponsor was involved in the study design, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.

1901. Venous Thromboembolism Risk Is Consistently Increased in People with Rheumatoid Arthritis Across Different Ages, Sexes and Obesity Status: United Kingdom Population Based Study
Study Sponsor: Pfizer
Sponsor Statement: This study was sponsored by Pfizer.

1902. Ixekizumab for the Treatment of Patients with Spondyloarthritis – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Study Sponsor: Eli Lilly
Sponsor Statement: This study was partly sponsored by Eli Lilly. Eli Lilly had no influence on the data collection, statistical analyses or preparation of this abstract and had no access to raw data.

1904. Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level
Study Sponsor: This abstract was supported by Janssen.
Sponsor Statement: This abstract was supported by Janssen.

1911. Improving Healthcare Access in Underserved Brooklyn Communities: A Comprehensive Multispecialty Patient Navigator Program
Study Sponsor: Aurinia Pharmaceuticals (rheumatology patient navigator program) and Janssen (dermatology patient navigator program)
Sponsor Statement: Aurinia Pharmaceutical provided funding for the rheumatology patient navigator program.

Janssen provided funding for the dermatology patient navigator program.

1912. Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Study Sponsor: Janssen Scientific Affairs, LLC
Sponsor Statement: This work was supported as an investigator-initiated study funded by Janssen Scientific Affairs, LLC

1935. Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians
Study Sponsor: Unrestricted research grant from Pfizer
Sponsor Statement: Unrestricted research grant

1943. Virtual Rheumatology in the Real World: Use of Telemonitoring to Optimize the Management of Patients with Rheumatoid Arthritis
Study Sponsor: Pfitzer
Sponsor Statement: This abstract is the result of a quality improvement project founded by Pfizer

(competitive grant)

1950. Telehealth Physical Therapy Intervention to Increase Physical Activity in Adults with Knee OA: The Delaware PEAK Randomized Controlled Trial
Study Sponsor: fNo
Sponsor Statement:

1952. Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry
Study Sponsor: GlaxoSmithKline
Sponsor Statement: RAY is supported in part by GSK. This sponsor was not directly involved in the conduct and reporting of the study.

1959. A 3-arm, Randomized, Open-label, Parallel Active Controlled, Multicentre International Study to Compare the Response of Ultrasound-assessed Synovitis to Baricitinib, Alone and Combined with Methotrexate versus Etanercept in Rheumatoid Arthritis Patients
Study Sponsor: This study was funded by an investigator-initiated research grant provided by Lilly S.A.U.
Sponsor Statement: Lilly did not participate in the study design, data collection, data analysis, or writing of the manuscript.

1965. Artificial Intelligence Assisted Interpretation of Lung Ultrasound Imaging for the Detection of Interstitial Lung Disease
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: This research was supported by an investigated initiated study award through Boehringer Ingelheim.

1967. Advanced Imaging in the Evaluation of Lupus Arthritis: A Systematic Literature Review and Meta-Analysis
Study Sponsor: This work was funded in part by U.S. Department of Defense, award #: W81XWH-22-1-0738.
Sponsor Statement:

1970. Validation of Handheld Ultrasound Devices for Point of Care Use in Rheumatology: Interim Analysis for Enthesitis
Study Sponsor: This study was funded by Novartis
Sponsor Statement:

1978.5. Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

1988. A Randomized, Open-Label Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

2001. Complications and Treatment Use Associated with Long-term Oral Corticosteroid Therapy Among Patients with Dermatomyositis or Polymyositis

Study Sponsor: Janssen Global Services
Sponsor Statement: This study was funded by Janssen Global Services, LLC.

2005. Impact of Anti-drug Antibodies on the Efficacy of SEL-212 in Patients with Chronic Gout Refractory to Conventional Therapy
Study Sponsor: Sobi
Sponsor Statement: The DISSOLVE I & II (NCT04513366 and NCT04596540) studies were jointly funded by Sobi and Selecta BioSciences, Inc and this publication was funded by Sobi.

2008. A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Dose of ABP-671 in Participants with Chronic Kidney Disease (CKD)
Study Sponsor: Atom Bioscience
Sponsor Statement: AtomBioscience funded this study

2010. The Influence of Treat-to-target Urate Lowering Therapy and Anti-inflammatory Prophylaxis on Circulating Measures of Inflammation in Gout
Study Sponsor: Horizon
Sponsor Statement: Horizon provided funding for the biomarkers assays used in this study. They did not provide input on conduct or reporting of the study.

2011. The Relationship Between Anti-drug Antibodies, Infusion Reactions, and Loss of Urate-lowering Response in Patients with Uncontrolled Gout Treated with Pegloticase
Study Sponsor: Horizon Therapeutics plc (now Amgen, Inc.)
Sponsor Statement: The MIRROR RCT trial was funded by Horizon Therapeutics plc (now Amgen, Inc.). This post hoc analysis was funded by Amgen, Inc. The sponsor played a role in analysis design, data analysis and interpretation, and abstract writing.

2012. Safety, Tolerability and Efficacy of Pegloticase Administered with a Shorter Infusion Duration in Subjects with Uncontrolled Gout Receiving Methotrexate: Primary Findings of the AGILE Open-label Trial
Study Sponsor: Horizon Therapeutics plc (now Amgen, Inc.)
Sponsor Statement: This study was sponsored by Horizon Therapeutics plc (now Amgen, Inc.). The study sponsor played a role in study design, data analysis and interpretation, and abstract writing. Medical writing and editing support was provided by Lissa Padnick-Silver PhD,

2019. Safety and Efficacy of SEL-212 in the US and ex-US Subgroups: Results from the Phase 3 DISSOLVE Studies
Study Sponsor: Sobi
Sponsor Statement: The DISSOLVE I & II (NCT04513366 and NCT04596540) studies were jointly funded by Sobi and Selecta BioSciences, Inc and this publication was funded by Sobi.

2047. Safety in Patients with Latent Tuberculosis Who Received Concomitant Anti-Tuberculosis Medications: Analysis of 11 Studies of Guselkumab in Psoriatic Disease
Study Sponsor: This study was sponsored by Janssen Research & Development, LLC
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

2048. Prognostic Value of Bronchoalveolar Lavage in CTD-related Interstitial Lung Disease: An Observational Study
Study Sponsor: Austrian Society of Rheumatology
Sponsor Statement:

2051. Clinical Outcomes and Predictors of Relapse in Patients with IgG4-Related Disease Treated with Rituximab: A Real-World Experience
Study Sponsor: Sanofi
Sponsor Statement: Sanofi provided funding for investigators involved in the design and execution of this study. Company representatives reviewed the study design and planned analysis but were not involved in data collection, analysis, or abstract preparation.

2056. Deucravacitinib Treatment Did Not Impact Immune Response to SARS-CoV-2 Vaccines and Infection in Patients with Plaque Psoriasis: Results from the Phase 3 POETYK Long-Term Extension Trial
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: We would like to thank the patients and families who made this study possible, as well as the clinical teams who participated. The study was supported by Bristol Myers Squibb. All authors contributed to and approved this abstract; professional medical wri

2093. Treatment of Advanced Knee OA with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial
Study Sponsor: Biosplice Therapeutics, Inc
Sponsor Statement: Biosplice Therapeutics, Inc., designed, funded and monitored the study. Biosplice also conducted data management and statistical analysis.

2106. EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate) Shows Sustained Improvement in Pain for Subjects with Moderate Baseline Pain and BMI Less Than 30 in SPRINGBOARD, a Phase 2, Randomized, 24-Week Study of Osteoarthritis of the Kne
Study Sponsor: Eupraxia Pharmaceuticals
Sponsor Statement: The funder of the trial (Eupraxia Pharmaceuticals Inc.) had a role in trial design, data collection, data analysis, data interpretation and writing of the report.

2111. An International Patient Survey to Identify Candidate Items for Classifying Early-Stage Symptomatic Knee Osteoarthritis
Study Sponsor: Grünenthal; Viatris Inc
Sponsor Statement: We would like to acknowledge the funding support for this initiative by Grünenthal and Viatris Inc. The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or

2115. Clinical Impact of Acute Symptomatic Vertebral Fractures in the United States: An Observational Study
Study Sponsor: Amgen Inc. and UCB Pharma
Sponsor Statement: This study was funded by Amgen Inc. and UCB Pharma

2116. Artificial Intelligence Classifier for Osteoporosis Detection from Chest Radiographs: Performance Evaluation and Literature Comparison with Quantitative Ultrasound
Study Sponsor: Promedius,inc.
Sponsor Statement: The primary author and presenter are employees of the company, Promedius,inc.

2119. IL-17 Blockade Therapy Improves Symptoms in Patients with Active Axial Spondyloarthritis Without Occurrence of New Vertebral Fractures
Study Sponsor: Novartis
Sponsor Statement: This study was funded by an investigator-initiated grant from Novartis Pharmaceuticals (grant number CAIN457FUS02T).

2123. Epidemiology of Bone Health and Fracture in Gout Patients
Study Sponsor: Amgen
Sponsor Statement: This study received funding from Amgen.

2124. Epidemiology of Bone Health and Fracture in Gout Patients
Study Sponsor: Amgen
Sponsor Statement: This study received financial support from Amgen.

2126. Analysis of the Evolution of Bone Mineral Density in the Spanish Population: Results of the OsteoSER Study
Study Sponsor: Hologic, UCB, Stada
Sponsor Statement: Hologic provided the diagnostic vehicle and the personnel necessary for its operation.

UCB and STADA provided funds for the development of the study.

None of the three participated in the study design or data analysis.

2144. Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
Study Sponsor: Celltron, Inc.
Sponsor Statement: This study was funded by Celltrion, Inc. (Incheon, Republic of Korea).

2149. Rheumatoid Arthritis: Patient's Voice First! An Original Approach Based on Infodemiology Using Social Media Content – Results from the PRIMA Study
Study Sponsor: NORDIC PHARMA FRANCE
Sponsor Statement: This study was funded by NORDIC PHARMA FRANCE

2150. Understanding Unmet Needs and Quality of Life Impact of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) Using Social Media: A Patient and Caregiver Perspective
Study Sponsor: Novartis Pharma AG, Basel, Switzerland
Sponsor Statement:

2208. Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: The IPF-PRO/ILD-PRO Registry is supported by Boehringer Ingelheim Pharmaceuticals, Inc. and run in collaboration with the Duke Clinical Research Institute (DCRI) and enrolling centers.

2219. Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort
Study Sponsor: Sandoz
Sponsor Statement: Sandoz Pharamaceuticals

2229. Aptamer Based Proteomic Profiling Demonstrates Significant Differences in Methotrexate Responders versus Non-responders in Newly Diagnosed Rheumatoid Arthritis and Adds Potential Value to Clinical Examination
Study Sponsor: Pfizer Canada

Sponsor Statement: Partially funded partially by Pfizer Canada as an Investigator Initiated Project. Pharmaceutical company had no role in design, interpretation nor dissemination of study

2231. Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort
Study Sponsor: Unrestricted research grants from Pfizer Canada- Founding sponsor since 2007; AbbVie since 2011; Sandoz Canada since 2019; Organon Canada since 2021; Nordic Pharma since 2023. Previous funding from Viatris Canada (2023); Jamp (BIOJAMP) (2023); Celltrion H
Sponsor Statement: The CATCH study was designed and implemented by the investigators.

2232. Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Study Sponsor: Exagen, Inc.
Sponsor Statement: This study was funded by Exagen, Inc.

2233. Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Study Sponsor: Exagen, Inc.
Sponsor Statement: This study was sponsored by Exagen, Inc.

2238. The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status
Study Sponsor: Pfizer
Sponsor Statement: The sponsor only provided funding. The sponsor was not involved in data collection, analysis or manuscript drafting

2239. Age, Seropositivity and Inflammation Determine Risk versus Benefit of Endogenous Estrogens on Coronary Atherosclerosis in Rheumatoid Arthritis
Study Sponsor: Pfizer
Sponsor Statement: The sponsor only funded the study. The sponsor was not involved in study design, data collection, formal analysis or abstract drafting

2240. Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis
Study Sponsor: Pfizer
Sponsor Statement: The sponsor only provided funding for the study. They had no input or involvement on design, data collection, analysis, interpretation, or manuscript drafting.

2245. Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs
Study Sponsor: Lilly
Sponsor Statement: Lilly partially sponsored this study. This sponsorship involved partial economic support and also one of the treatments administered to patients included in the study (Baricitinib).

2252. Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results from a Post Hoc Analysis of the FINCH 4 Study
Study Sponsor: Gilead Sciences, Inc., Galapagos NV
Sponsor Statement: We thank the physicians and patients who participated in this study. The FINCH studies were co-funded by Gilead Sciences, Inc. (Foster City, CA, USA) and Galapagos NV (Mechelen, Belgium). Medical writing support was provided by Debbie Sherwood, BSc, CMPP

2253. A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers
Study Sponsor: Zenas BioPharma
Sponsor Statement: This study was sponsored by Zenas Biopharma. Zenas Biopharma was involved in the design of the study, the collection, analysis, and interpretation of data, and the writing of the abstract. Zenas Biopharma also provided the study drug, as well as funding f

2254. A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers
Study Sponsor: Zenas BioPharma
Sponsor Statement: This study was sponsored by Zenas Biopharma. Zenas Biopharma was involved in the design of the study, the collection, analysis, and interpretation of data, and the writing of the abstract. Zenas Biopharma also provided the study drug, as well as funding f

2265. Patient's Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study
Study Sponsor: AbbVie
Sponsor Statement: AbbVie funded this study and contributed to its design, research, analysis, data collection, interpretation of data, and the review and approval of this abstract. Medical writing support was funded by AbbVie.

2267. A Novel Blood-based Assay That Predicts Clinical Response to TNFα Inhibitors or Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis
Study Sponsor: Aqtual Inc.
Sponsor Statement: This research was funded by Aqtual Inc. and partially executed by Aqtual employees.

2269. Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial
Study Sponsor: Sanquin Diagnostic Services
Sponsor Statement: Funded by Netherlands Organisation for Health Research and Development and Sanquin Diagnostic Services.

2272. Evolution of Methotrexate and Prednisone Use in the Era of Biologic Therapy: 15-Year Findings from a Large Rheumatoid Arthritis Registry
Study Sponsor: No. The abstract was not sponsored. The data for the abstract have been collected by CorEvitas a for profit organisation to which Pharma companies are clients.
Sponsor Statement: NOT APPLICABLE

2273. Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study
Study Sponsor: The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Pfizer Canada- Founding sponsor since 2007; AbbVie Corporation since 2011; Sandoz Biopharmaceuticals Canada since 2019; O
Sponsor Statement: The CATCH study was designed and implemented by the investigators and financially supported through unrestricted research grants from Pfizer Canada- Founding sponsor since 2007; AbbVie Corporation since 2011; Sandoz Biopharmaceuticals Canada since 2019; O

2274. Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial
Study Sponsor: Synact Pharma ApS
Sponsor Statement: The study was sponsored by Synact Pharma ApS. Synact Pharma was involved in study design, conduct, data analysis and abstract writing.

2275. Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
Study Sponsor: This abstract is not funded by any pharmaceutical or biotech company, but the registry BIOBADASER has received funding from Abbvie, Galapagos, Pfizer, Janssen, Sanofi and UCB
Sponsor Statement:

2280. Development of a Blood-based Cell-free DNA Classifier Assay to Predict Biologic and Targeted Synthetic DMARDs Response in Rheumatoid Arthritis Patients (PRIMA-102)
Study Sponsor: Aqtual Inc.
Sponsor Statement: The study was sponsored and executed by employees of Aqtual Inc.

2281. Assessment of Comparative Efficacy Between Candidate Biosimilar AVT05 and Reference Golimumab
Study Sponsor: Alvotech
Sponsor Statement: This study was funded by Alvotech.

2283. Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry
Study Sponsor: CorEvitas, LLC and Pfizer
Sponsor Statement: Study funded and sponsored by Pfizer and registry sponsored by CorEvitas, LLC. Medical writing support, under the direction of the authors, was provided by Lewis C Rodgers, PhD, CMC Connect, a division of IPG Health Medical Communications, and was funded

2286. Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Study Sponsor: UCB Pharma
Sponsor Statement: This study was funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

2290. Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren's Syndrome Pathology
Study Sponsor: Cell Exosome Therapeutics Inc.
Sponsor Statement:

2294. Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren's Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

2304. Differential Diagnosis of Sjogren's vs Non-Sjogren's Dry Eye
Study Sponsor: Novartis
Sponsor Statement: The study was supported in part by an institutional research grant paid to the Johns Hopkins University.

2316. Gene Expression Profile Is Different Between Men and Women in Psoriatic Disease
Study Sponsor: Janssen
Sponsor Statement: This study is an academic study (investigator initiated trial).

The sponsor of the study is the university hospital (Cliniques universitaires Satint-Luc).

Janssen companie support by giving a grant, without implication in the design and management of the

2325. Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
Study Sponsor: Novartis
Sponsor Statement: Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

2326. Development and Evaluation of a Machine Learning Model for the Early Identification of Psoriatic Arthritis
Study Sponsor: Predicta-Med LTD
Sponsor Statement: This study was funded and conducted by Predicta-Med LTD

2334. Characteristics of Patients with Psoriatic Arthritis Presenting with Axial Involvement: Results of a Prospective International Multicenter Study (AXIS)
Study Sponsor: Abbvie, Alfasigma, Jannsen, Lilly, Pfizer, UCB, and Novartis.
Sponsor Statement: AXIS was supported by unrestricted research grants from Abbvie, Alfasigma, Jannsen, Lilly, Pfizer, UCB, and Novartis.

2335. Hand Function and Development of Psoriatic Arthritis in Skin Psoriasis Patients, a Prospective Cohort Study
Study Sponsor: Novartis Pharma GmbH, Germany and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – SFB 1483 – Project-ID 442419336, EmpkinS.
Sponsor Statement: This work was partly funded by Novartis Pharma GmbH, Germany and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – SFB 1483 – Project-ID 442419336, EmpkinS.

2340. Direct to Patient Screening for Psoriatic Arthritis in Patients with Psoriasis: Diagnosis Rates, Referral Pathways, and Educational Value of Screening
Study Sponsor: Pfizer
Sponsor Statement: This study was funded by an investigator initiated grant from Pfizer

2341. Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis
Study Sponsor: Nimbus Discovery, Inc. and Takeda Development Center Americas, Inc.
Sponsor Statement: This study was funded by Nimbus Discovery, Inc. and Takeda Development Center Americas, Inc. Nimbus refers to the group of entities including Nimbus Therapeutics LLC, Nimbus Discovery, Inc. and Nimbus Lakshmi, Inc. (NB: Nimbus Lakshmi, Inc. was acquired b

2342. Guselkumab Shows Similar Domain-Specific Efficacy in Females and Males with Active Psoriatic Arthritis: Post Hoc Analyses of Three Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Study Sponsor: Janssen Research & Development, LLC sponsored the clinical trial(s) providing data for this abstract
Sponsor Statement:

2344. Secukinumab Retention and Effectiveness in Patients with Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: 5-year Final Results of a Prospective Real-world Study
Study Sponsor: Novartis Pharma AG, Basel, Switzerland
Sponsor Statement: This study was sponsored by Novartis Pharma AG, Basel, Switzerland.

2348. Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Editorial support provided by Costello Medical and funded by UCB Pharma.

2350. Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
Study Sponsor: Novartis Pharma AG
Sponsor Statement: The EuroSpA collaboration was financially supported by Novartis. Novartis had no influence on the data collection, statistical analyses, abstract preparation or decision to submit.

2351. Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

2352. Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

2353. Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

2354. Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial
Study Sponsor: Novartis Pharmaceuticals Corporation, East Hanover, NJ
Sponsor Statement: This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. The funding source was involved in study design, data analysis, drafting, and approval of this abstract. Medical writing support was provided by Ken Gresham, PhD, CMPP, of

2355. Efficacy of Risankizumab Across Distinct PsA Phenotypes Identified with Machine Learning Analytics Using Data from Biologic DMARD-Naive Patients in Two Phase 3 Clinical Trials
Study Sponsor: AbbVie
Sponsor Statement: AbbVie funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had access to relevant data and participated in the drafting, review, and appr

2356. Baseline Characteristics of Patients with Psoriatic Arthritis Treated with Ixekizumab or Interleukin-23 Inhibitors and Interim Effectiveness Results from an Observational Study in the US

Study Sponsor: This abstract was funded by Eli Lilly and Company.
Sponsor Statement: This study was funded by Eli Lilly and Company, which contributed to study design, data collection, data analysis, data interpretation, manuscript preparation, and publication decisions.

2357. Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studie
Study Sponsor: This study was sponsored by Janssen Research & Development, LLC
Sponsor Statement:

2359. A Real-World Study on the Clinical Characteristics and Patient Reported Outcomes of Patients with Active AxSpA Prescribed CT-P13 SC in Five European Countries
Study Sponsor: Celltrion, Inc.
Sponsor Statement: Celltrion was one of multiple subscribers to the DSP and did not influence the original survey through either contribution to the design of questionnaires or data collection.

2360. Patient Selection and Treatment Outcomes Using Preliminary Data-driven Definition versus the Established ASAS Definition of a Positive MRI of the Sacroiliac Joint in axSpA: Post-hoc Analysis from COAST-X
Study Sponsor: Eli Lilly and Company
Sponsor Statement: The study was sponsored by Eli Lilly and Company

2361. Assessment of Laboratory Parameter Changes in a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Highly Selective TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis
Study Sponsor: Nimbus Discovery, Inc. and Takeda Development Center Americas, Inc.
Sponsor Statement: This study was funded by Nimbus Discovery, Inc. and Takeda Development Center Americas, Inc. Nimbus refers to the group of entities including Nimbus Therapeutics LLC, Nimbus Discovery, Inc. and Nimbus Lakshmi, Inc. (NB: Nimbus Lakshmi, Inc. was acquired b

2362. Achievement of Remission Defined by Absence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

2363. “How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

2364. Reporting Mental Health and Associated Disorders from Trials of Bimekizumab in Patients with Active Axial Spondyloarthritis and Psoriatic Arthritis
Study Sponsor: UCB Pharma
Sponsor Statement: This study was funded by UCB Pharma. Editorial services provided by Costello Medical and funded by UCB Pharma.

2365. Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis

Registry
Study Sponsor: AbbVie
Sponsor Statement: The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. This study is sponsored by CorEvitas, LLC. CorEvitas has been supported throug

2366. Improvement in Pain-Associated Biomarkers with Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with PsA in a Double-Blind Phase 2 Study (IM011-084)
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: We would like to thank the patients and families who made this study possible, as well as the clinical teams who participated. The study was supported by Bristol Myers Squibb. All authors contributed to and approved this abstract; professional medical wri

2367. Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

2368. Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Study Sponsor: UCB Pharma
Sponsor Statement: Funded by UCB Pharma. Medical writing support provided by Costello Medical and funded by UCB Pharma.

2369. Impact of Baseline Factors on Disease Progression and Apremilast Efficacy in Early Oligoarticular Psoriatic Arthritis
Study Sponsor: Amgen Inc.
Sponsor Statement: This study was sponsored by Amgen Inc. Writing support was funded by Amgen Inc. and provided by Christina Mulvihill, PharmD, of Peloton Advantage, LLC, an OPEN Health company, and Claire Desborough, employee of and stockholder in Amgen Inc.

2401. A Novel Modeling Approach to Elucidate the Role of Autoantibodies in Complement Activation in SLE
Study Sponsor: Immunovant
Sponsor Statement: This work was supported by funding from Immunovant.

2402. Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis
Study Sponsor: This analysis was funded by GSK
Sponsor Statement:

2409. Adherence to EULAR Recommendations and Sub Optimal Management of Systemic Lupus Erythematosus in a Network of Community-Based Rheumatology Practices in the United States
Study Sponsor: AstraZeneca
Sponsor Statement: This study was sponsored by AstraZeneca.

2411. Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study
Study Sponsor: Funding: GSK: 217855

Sponsor Statement: Role of the Study Sponsor: GSK funded the analytical component of the study, and was involved in study design, results interpretation, and publication development.

2415. Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
Study Sponsor: Aurinia Pharmaceuticals, Inc.
Sponsor Statement: This study was supported by Aurinia Pharmaceuticals, Inc.

2416. The Impact of Active Lupus Nephritis on Work Productivity in Patients from a Latin American Lupus Cohort
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

2417. Frequency and Associated Factors of Herpes Zoster Infection in Systemic Lupus Erythematosus Patients from Latin-America
Study Sponsor: GlaxoSmithKline (GSK)
Sponsor Statement: Funding or product for this study was provided by 'GSK Biologicals SA. GSK Biologicals SA was provided with the opportunity to review a preliminary version of this abstract for factual accuracy, but the authors are solely responsible for the final content

2418. Identification of Co-expressed Molecular Markers That Predict Risk of Severe Flare in Patients with Systemic Lupus Erythematosus (SLE)
Study Sponsor: Eli Lilly
Sponsor Statement: The clinical trials, data generation and analyses were funded by Eli Lilly.

2419. Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data
Study Sponsor: AstraZeneca
Sponsor Statement: This study was sponsored by AstraZeneca. Writing assistance was provided by Vasileios Stamou, PhD, of JK Associates Inc., part of Avalere Health, and funded by AstraZeneca.

2422. Development of a Multiplexed-engineered, Off-the-shelf CAR NK Cell with Unique Multi-Pathogenic Cell Targeting Capacity for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Study Sponsor: Fate Therapeutics
Sponsor Statement: The research contained in this abstract was sponsored by Fate Therapeutics.

2424. Anifrolumab Effects on Response to Influenza Vaccine in SLE
Study Sponsor: Astra Zeneca
Sponsor Statement: The protocol was developed and conducted by the authors. Astra Zeneca funded the study and added requirements to the entry criteria and reporting, including help with the clinical trial report. The abstract was written by the authors and approved by Astra

2425. Ianalumab Induced Durable Depletion of Circulating B Cell Subsets and Associated Changes in B Cell and Neutrophil Transcriptomic and Proteomic Profiles in Patients with Systemic Lupus Erythematosus: 52-Week Treatment Results from a Phase 2 Trial
Study Sponsor: Novartis Pharma AG
Sponsor Statement: The study is sponsored by Novartis Pharma AG, Basel, Switzerland.

2430. Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a

Phase 2b Trial
Study Sponsor: UCB Pharma and Biogen Inc.
Sponsor Statement: This study was funded by UCB Pharma and Biogen Inc. Medical writing and editorial support was provided by Costello Medical and funded by UCB Pharma and Biogen Inc.

2431. DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use
Study Sponsor: AstraZeneca
Sponsor Statement: This study was sponsored by AstraZeneca.

2432. In Vitro and In Vivo Evidence of the Steroid-Sparing Potential of Afimetoran, an Equipotent Toll-Like Receptor 7/8 Dual Antagonist
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: This study was supported by Bristol Myers Squibb.

2434. ESK-001, an Allosteric TYK2 Inhibitor, Maximally Suppresses Type 1 Interferon, a Therapeutic Pathway Central to SLE and CLE
Study Sponsor: Alumis
Sponsor Statement: Commercial support was provided by Alumis Inc. All authors are employed by Alumis.

2436. Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
Study Sponsor: F. Hoffmann-La Roche Ltd.
Sponsor Statement: The study has been financed and conducted by F. Hoffmann-La Roche Ltd.

2438. Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
Study Sponsor: AstraZeneca
Sponsor Statement:

2439. Preliminary Analysis of Open-Label Dose-Titration Phase of SLE Treatment with N-Acetylcysteine (SNAC) Shows Evidence for Potential Improvement of SLEDAI, BILAG, ADHD and Fatigue Scores in Patients with Active SLE
Study Sponsor: This study is funded by NIH/NIAMS.
Sponsor Statement:

2462. A Potent Inhibitor of PAI-1, MDI-2517, Mitigates Disease Severity in Preclinical Models of Systemic Sclerosis
Study Sponsor: MDI Therapeutics
Sponsor Statement: This work was sponsored in part by MDI Therapeutics through subcontracts from MDI Therapeutics for National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health awards R43AR074318 and R44AR074318, and the Natio

2466. Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease
Study Sponsor: Boehringer Ingelheim
Sponsor Statement: The SENSCIS trial was supported by Boehringer Ingelheim.

2476. The Impact of Systemic Sclerosis Manifestations on Survival and Humanistic Burden: A Targeted Literature Review

Study Sponsor: Boehringer Ingelheim International GmbH
Sponsor Statement: This study was supported and funded by Boehringer Ingelheim International GmbH. BI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.

2478. Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial
Study Sponsor: Amgen
Sponsor Statement: The ADVOCATE study was funded by ChemoCentryx, Inc. (a wholly owned subsidiary of Amgen Inc.). Amgen supported this post hoc analysis and the medical writing for this abstract, provided by Martha Mutomba, PhD on behalf of Amgen.

2479. Mepolizumab Treatment Decreased Oral Corticosteroid Use and Improved Clinical Response, Control Status, and Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis: Results up to 24 Months from a Large Network of US Allergy Practices
Study Sponsor: GSK (218960)
Sponsor Statement: GSK was involved in study design and implementation, as well as data collection, analysis, interpretation, writing the study report and reviewing this abstract. GSK did not place any restrictions on access to data or statements made in the abstract. All a

2480. Avacopan versus a Prednisone Taper in Patients with ANCA-Associated Vasculitis and Ear, Nose, or Throat Involvement in a Phase 3 Trial
Study Sponsor: Amgen
Sponsor Statement: The ADVOCATE study was funded by ChemoCentryx, Inc. (a wholly owned subsidiary of Amgen Inc.). Amgen supported this post hoc analysis. Amgen funded the medical writing and editorial assistance for this abstract, provided by Maartje Wouters, PhD and Saimah

2481. General, Nervous System, Eye, and Skin Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Study Sponsor: Amgen
Sponsor Statement: The ADVOCATE study was funded by ChemoCentryx, Inc. (a wholly owned subsidiary of Amgen Inc.). Amgen supported this post hoc analysis and the medical writing for this abstract, provided by Kelly Miller, MPH (Peloton Advantage, LLC, an OPEN Health company)

2482. Long-Term Safety of Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pooled Results from Two Open-Label Extension Studies
Study Sponsor: GSK
Sponsor Statement: GSK was involved in study design and implementation, as well as data collection, analysis, interpretation, writing the study report and reviewing this abstract. GSK did not place any restrictions on access to data or statements made in the abstract. All a

2488. Patient Characteristics and Treatment Patterns Before and After Initiation of Avacopan in the United States: An Early View Based on a Claims Database Analysis
Study Sponsor: Amgen
Sponsor Statement: This study was funded by Amgen Inc.

2489. Avacopan for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in a Real-World Setting
Study Sponsor: Amgen
Sponsor Statement: Amgen sponsored this research study. All data was collected and analyzed

independently by the staff at Mass General, led by the senior author. Amgen co-authors provided input on the study design and the abstract but the final decision to publish was made

2491. Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data
Study Sponsor: AstraZeneca
Sponsor Statement: This analysis was funded by AstraZeneca, which was involved in the study design and interpretation of the study results and funded medical writing support. AstraZeneca also reviewed the publication, without influencing the opinions of the authors, to ensu

2503. Hypothalamic-Pituitary-Adrenal Axis Suppression by Prednisolone Reversed by the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor Clofutriben
Study Sponsor: Sparrow Pharmaceuticals
Sponsor Statement: Sparrow Pharmaceuticals employees led the design, conduct, analysis, and reporting of the clinical trial.

2513. Frequency, Diagnosis, and Management of Polymyalgia Rheumatica in Germany – Database Analysis of Medical Insurance Data
Study Sponsor: Novartis Pharma GmbH
Sponsor Statement: Study was sponsored by Novartis Pharma GmbH

2518. Behçet's Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype
Study Sponsor: Funded by the NIH
Sponsor Statement:

2520. Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Study Sponsor: AbbVie Inc.
Sponsor Statement: AbbVie funded this analysis and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, an

2527. Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren's Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS)
Study Sponsor: Janssen Research & Development
Sponsor Statement: This study was sponsored by Janssen Research & Development, LLC

2528. Activation of the Hes1/Piezo1 Pathway Promotes Mechanical Stress Response and Prevents Glucocorticoid-induced Osteoporosis
Study Sponsor: Taisho Pharmaceutical Co., Ltd.
Sponsor Statement: Funding was provided by Taisho Pharmaceutical Co. Ltd.

2531. CRISPR Deletion Screen in Fibroblasts Identifies Novel Regulators of Inflammation
Study Sponsor: Johnson & Johnson
Sponsor Statement: Johnson & Johnson provided funding for the CRISPR screen and studies described in the abstract. Their team was not responsible for carrying out experiments, performing data analysis, or reporting of results, though they offered intellectual contributions

2537. Sjögren's Disease and Non-Sjögren's Sicca Patient Subsets Exhibit Cell Type-specific Transcriptional Dysregulations That May Identify Early Molecular Predictors of Disease Transition
Study Sponsor: Johnson and Johnson Innovative Medicine (formerly Janssen)
Sponsor Statement: Johnson and Johnson Innovative Medicine (formerly Janssen) provided a grant/research support for this study (Funding ended 12/31/2023).

2543. Novel IgG Degrader BHV-1300 Demonstrates the Ability to Remove Anti-bDMARD ADA and Allows for Co-administration with Fc-containing Biologics
Study Sponsor: Biohaven Pharmaceuticals
Sponsor Statement: Biohaven Pharmaceuticals conducted the research and analyzed the data.

2553. Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Study Sponsor: Quality Improvement grant from Sandoz UK.
Sponsor Statement: This work was supported by a Quality Improvement grant from Sandoz UK. No funding bodies had any role in study design, data collection, analysis or interpretation, manuscript writing, or in the decision to submit the article for publication.

2563. Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
Study Sponsor: Celltrion, Inc.
Sponsor Statement: This study was funded by Celltrion, Inc. (Incheon, Republic of Korea).

2565. A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab-1000 and Prolia in Postmenopausal Women with Osteoporosis
Study Sponsor: This study was sponsored by Biocon Biologics UK Limited
Sponsor Statement: This study was sponsored by Biocon Biologics UK Limited

2566. Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
Study Sponsor: Multiple
Sponsor Statement: Rh-GIOP is or was supported by a joint funding of Abbvie, Amgen, Almirall, Biogen, BMS, Chugai, Galapagos, Generic Assays, GSK, Hexal, Horizon Therapeutics, Lilly, Medac, Mundipharma, Novartis, Pfizer, Roche, Sanofi-Genzyme, and UCB.

The Parker Institute

2573. Efficacy and Safety of Ixekizumab in Children with Active Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis (COSPIRIT-JIA): 16-week Results of a Multicentre, Randomised, Open-label Study
Study Sponsor: Eli Lilly and Company
Sponsor Statement: The study was sponsored by Eli Lilly and Company

2577. Efficacy and Safety of ABBV-599 (Elsubrutinib and Upadacitinib Combination) and Upadacitinib Monotherapy for the Treatment of Systemic Lupus Erythematosus: Results Through 104 Weeks in a Long-Term Extension Study
Study Sponsor: AbbVie
Sponsor Statement: The authors thank Dr Alan Friedman for his contributions to this study. AbbVie

funded this study and participated in the study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the abstract. All authors had ac

2578. Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
Study Sponsor: Eisai Co., Ltd.
Sponsor Statement: Eisai Company, Ltd. was involved in study design, data collection, analysis, and interpretation of data. The corresponding author had full access to all data and had responsibility for the decision to submit for publication.

2580. Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Study Sponsor: Novartis
Sponsor Statement: The study was sponsored by Novartis Pharma AG, Basel, Switzerland.

2581. Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Study Sponsor: Jiangsu Hengrui Pharmaceuticals Co., Ltd
Sponsor Statement:

2582. Efficacy and Safety of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Patients with Active PsA: 24-Week Results from a Global, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Study Sponsor: MoonLake Immunotherapeutics
Sponsor Statement: This study was funded by MoonLake Immunotherapeutics. The funders participated in the collection, analysis, and interpretation of data; in the writing of the abstract; and in the decision to submit the abstract

2583. Apremilast Reduces Axial Inflammation in Patients with Psoriatic Arthritis as Assessed by CANDEN MRI Scoring: Results from a Phase 4 Study
Study Sponsor: Amgen Inc.
Sponsor Statement: This study was funded by Amgen Inc.

2584. Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
Study Sponsor: Nimbus Discovery, Inc., and Takeda Development Center Americas, Inc.
Sponsor Statement: This study was funded by Nimbus Discovery, Inc., and Takeda Development Center Americas, Inc. Nimbus refers to the group of entities including Nimbus Therapeutics LLC, Nimbus Discovery, Inc., and Nimbus Lakshmi, Inc. (NB: Nimbus Lakshmi, Inc., was acquire

2585. Guselkumab and IL-17 Inhibitors Improve Patient-perceived Impact of Psoriatic Arthritis Similarly: 6-month Interim Results of the PsABIOnd Observational Cohort Study
Study Sponsor: Janssen
Sponsor Statement: Janssen funded this study.

2586. Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
Study Sponsor: Novartis Pharma GmbH

Sponsor Statement: Novartis Pharma GmbH provided funding, did not influcence the data interpretation and result presentation.

2594. A Novel Therapeutically Active CSF-1R Agonist Promotes Tissue Macrophages Inflammation Resolution and Induces Tissue Repair Pathways
Study Sponsor: Nektar Therapeutics
Sponsor Statement: All work in this abstract was sponsored by Nektar Therapeutics.

2598. p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines
Study Sponsor: Kronos Bio
Sponsor Statement: Kronos Bio, a publicly-traded biopharmaceutical company, funded the studies described in this abstract

2610. Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Study Sponsor: The trial was partially sponsored by Sanofi.
Sponsor Statement: The trial was partially sponsored by Sanofi. Sanofi employees were not involved in the design and conduct of the study. They did not contribute to the collection, analysis, and interpretation of data. They did not support the authors in the development of

2612. Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study
Study Sponsor: "Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo and GSK.
Sponsor Statement: Funding for this investigator initiated study was provided by GSK [NCT05879419]. GSK was provided the opportunity to review a preliminary version of this publication for factual accuracy, but the authors are solely responsible for final content and interp

2614. Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
Study Sponsor: We thank the Colombian Association of Rheumatology (ASOREUMA) for their support. This work was supported by the Ministerio de Ciencia, Tecnología e Innovación de Colombia, MinCiencias, as part of the AGORA Project.: “Alianza para la Generación de evidenci
Sponsor Statement:

2629. Deciphering Salivary Gland Inflammation in Sjögren's Syndrome Reveals Shared and Autoantibody-Specific Immune Cell Heterogeneity
Study Sponsor: Research funding; Ono Pharmaceutical CO., LTD., Daiichi Sankyo CO., LTD., and Mitsubishi Tanabe Pharma CO.
Sponsor Statement:

2630. Identification of Molecular Biomarkers for Sjögren's Disease Stratification via a Deep Learning Foundation Model Dedicated to Immune-Mediated and Inflammatory Disease
Study Sponsor: Scienta Lab (SL); Institut de Recherche Internationales Servier (IRIS)
Sponsor Statement: SL and IRIS conceptualized the study

SL built the prediction models, analysed the data, and wrote the abstract

All authors reviewed the final abstract.

2634. Transcriptomic Stratification Predicts Response to Rituximab, Abatacept or the Association of Hydroxychloroquine and Leflunomide in 3 Randomized Controlled Clinical Trials in Sjögren's Disease
Study Sponsor: European Union's Horizon 2020 research and innovation program and EFPIA.
Sponsor Statement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) NECESSITY under grant agreement No 806975. The JU receives support from the European Union's Horizon 2020 research and innovation program and EFPIA. The pr

2636. Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)
Study Sponsor: The study was sponsored by Atturos - a UCD (University) spin-out SME/company (www.atturos.com)
Sponsor Statement: The sponsor of this study, Atturos, provided funding and contributed to the design of the study and interpretation of the data.

2641. Identification of Systemic Sclerosis Intrinsic Subtypes in the ASSET Clinical Trial Using PBC Gene Expression
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: This work was funded in part by a grant from Bristol Myers Squibb (BMS) who had not role in the design of the study or the interpretation of the results.

2662. In Vivo Generation of B Cell Depleting CAR T Cell Therapies for Treatment of Autoimmune Diseases
Study Sponsor: Umoja Biopharma Inc
Sponsor Statement: Umoja Biopharma has sponsored all activities described in this work.

2663. ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Study Sponsor: Adicet Bio
Sponsor Statement: The role of the study sponsor, Adicet Therapeutics, was to fund and execute the work reported in this abstract.

2671. Subcutaneous Abatacept vs Adalimumab Head-to-Head Comparison in Adults with Early, Dual Seropositive Rheumatoid Arthritis, Positive for the Shared Epitope HLA Class II Risk Alleles, and an Inadequate Response to Methotrexate: Results from a Phase 3 Trial
Study Sponsor: Bristol Myers Squibb
Sponsor Statement: This study was sponsored by Bristol Myers Squibb

2674. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States
Study Sponsor: AbbVie
Sponsor Statement: The design, study conduct, and financial support for the study was provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the abstract. No honoraria or payments were made for authorship. Medical writing services pro

2676. Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study
Study Sponsor: PFIZER

Sponsor Statement: Pfizer provided PCV13 vaccine. Pfizer realized OPA dosages. Pfizer gave a grant of 130 948 € on a total budget of 457 515 €

2680. Thrombocytopenia in Patients with Systemic Lupus ErythematosusReal-World Data Based on a Nationwide Database, RISE
Study Sponsor: Institutional
Sponsor Statement:

2681. Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021
Study Sponsor: Merck
Sponsor Statement: The study was funded by Merck's Investigator Initiated Studies program. The findings in the study do not represent official views of Merck.

2685. Association Between Gastrointestinal Bacterial Species and Radiological Features of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD): A Multicenter Study from the SSc Microbiome Consortium Project
Study Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.
Sponsor Statement: This was an independent, investigator initiated study supported by Boehringer Ingelheim Pharmaceuticals, Inc. [BIPI]. BIPI had no role in the design, analysis or interpretation of the results in this study; BIPI was given the opportunity to review the pub

2686. Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells
Study Sponsor: Seagen/Pfizer
Sponsor Statement: The work was conducted by the Immune Tolerance Network and supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (UM1-AI-109565). Study medication and partial funding was provided by Seagen/Pfizer.

2689. Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis
Study Sponsor: Takeda Pharmaceuticals.
Sponsor Statement: This study was supported in part by Takeda Pharmaceuticals. This included contributions to the study design, completion, and data analysis, all in collaboration with the Vasculitis Clinical Research Consortium.

2691. Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis
Study Sponsor: GSK
Sponsor Statement: Funded by GSK